<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11680170</article-id><article-id pub-id-type="doi">10.3390/vaccines12121312</article-id><article-id pub-id-type="publisher-id">vaccines-12-01312</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Antibody Response to SARS-CoV-2 Vaccines in Transplant Recipients and Hemodialysis Patients: Data from the Dominican Republic</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7339-1124</contrib-id><name><surname>Alcantara Sanchez</surname><given-names>Lisette</given-names></name><xref rid="af1-vaccines-12-01312" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0120-588X</contrib-id><name><surname>Alvarez Guerra</surname><given-names>Eloy</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="af2-vaccines-12-01312" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9140-2483</contrib-id><name><surname>Li</surname><given-names>Dongmei</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="af1-vaccines-12-01312" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3568-7597</contrib-id><name><surname>King</surname><given-names>Samantha M.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af3-vaccines-12-01312" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1950-7381</contrib-id><name><surname>Hilchey</surname><given-names>Shannon P.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af3-vaccines-12-01312" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0003-9215-8808</contrib-id><name><surname>Zhou</surname><given-names>Qian</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af3-vaccines-12-01312" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7729-7920</contrib-id><name><surname>Dewhurst</surname><given-names>Stephen</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af4-vaccines-12-01312" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3613-8012</contrib-id><name><surname>Fiscella</surname><given-names>Kevin</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af5-vaccines-12-01312" ref-type="aff">5</xref><xref rid="fn1-vaccines-12-01312" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7095-8682</contrib-id><name><surname>Zand</surname><given-names>Martin S.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-vaccines-12-01312" ref-type="aff">1</xref><xref rid="af3-vaccines-12-01312" ref-type="aff">3</xref><xref rid="af6-vaccines-12-01312" ref-type="aff">6</xref><xref rid="c1-vaccines-12-01312" ref-type="corresp">*</xref><xref rid="fn1-vaccines-12-01312" ref-type="author-notes">&#x02020;</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Pincus</surname><given-names>Seth</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vaccines-12-01312"><label>1</label>Clinical and Translational Science Institute, University of Rochester, Rochester, NY 14642, USA; <email>lisette_alcantara@urmc.rochester.edu</email> (L.A.S.); </aff><aff id="af2-vaccines-12-01312"><label>2</label>Instituto Nacional de Coordinaci&#x000f3;n de Trasplante, Instituto de Medicina Tropical y Salud Global, Universidad Iberoamericana, Santo Domingo 01219, Dominican Republic; <email>e.alvarez1@prof.unibe.edu.do</email></aff><aff id="af3-vaccines-12-01312"><label>3</label>Department of Medicine, Division of Nephrology, University of Rochester, Rochester, NY 14642, USA<email>qian_zhou@urmc.rochester.edu</email> (Q.Z.)</aff><aff id="af4-vaccines-12-01312"><label>4</label>Department Microbiology and Immunology, University of Rochester, Rochester, NY 14642, USA</aff><aff id="af5-vaccines-12-01312"><label>5</label>Department of Family Medicine, University of Rochester, Rochester, NY 14642, USA; <email>kevin_fiscella@urmc.rochester.edu</email></aff><aff id="af6-vaccines-12-01312"><label>6</label>Department of Public Health Sciences, University of Rochester, Rochester, NY 14642, USA</aff><author-notes><corresp id="c1-vaccines-12-01312"><label>*</label>Correspondence: <email>martin_zand@urmc.rochester.edu</email></corresp><fn id="fn1-vaccines-12-01312"><label>&#x02020;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>23</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><volume>12</volume><issue>12</issue><elocation-id>1312</elocation-id><history><date date-type="received"><day>27</day><month>9</month><year>2024</year></date><date date-type="rev-recd"><day>01</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>07</day><month>11</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><bold>Background</bold>: The global COVID-19 pandemic has resulted in approximately 7 million deaths and a historic vaccination effort, with over 13.6 billion doses administered. Despite this, understanding of immune responses in vulnerable populations, such as transplant recipients (TR) and hemodialysis patients (HD), remains limited, especially outside the US and Europe. <bold>Methods</bold>: To address this gap, we analyzed blood samples and deidentified data from the Instituto Nacional de Coordinaci&#x000f3;n de Trasplante (INCORT) in The Dominican Republic, measuring antibody levels to SARS-CoV-2 post-infection and vaccination with BNT162b2 (Pfizer-BioNTech) and Sinovac-CoronaVac (Sinovac) in TR, HD, and healthy controls (CO). Using a fluorescent multiplex assay (mPlex-CoV) and mixed-effects modeling, we assessed variations in anti-S, anti-RBD, and anti-N IgG antibodies. <bold>Results</bold>: The results indicate that the CO group experienced an early peak in anti-S and anti-RBD antibodies, followed by stabilization. In contrast, the TR and HD groups showed a slower, gradual increase in antibodies. Despite fluctuations in the HD group, both the TR and HD groups maintained high anti-S and anti-RBD IgG levels, indicating a back-boosting effect from vaccination. However, elevated anti-N IgG levels in the TR and HD groups suggest potential reinfections. Additionally, prior SARS-CoV-2 infection led to higher anti-S IgG levels, with BNT162b2 associated with higher anti-S IgG and CoronaVac associated with higher anti-N IgG levels. <bold>Conclusion</bold>: These findings highlight the variability in antibody responses and the need for targeted public health strategies to diverse immunological profiles.</p></abstract><kwd-group><kwd>COVID-19</kwd><kwd>SARS-CoV-2 vaccine</kwd><kwd>transplant recipients</kwd><kwd>hemodialysis</kwd><kwd>immunocompromised</kwd><kwd>antibody response</kwd><kwd>anti-S</kwd><kwd>anti-N</kwd></kwd-group><funding-group><award-group><funding-source>National Center for Advancing Translational Sciences of the National Institutes of Health</funding-source><award-id>UL1 TR002001</award-id><award-id>TL1 TR002000</award-id></award-group><funding-statement>This research was funded by the University of Rochester Clinical and Translational Science Awards (UL1 TR002001, TL1 TR002000) from the National Center for Advancing Translational Sciences of the National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-vaccines-12-01312"><title>1. Introduction</title><p>The coronavirus disease 2019 (COVID-19) global pandemic has resulted in approximately 7 million deaths [<xref rid="B1-vaccines-12-01312" ref-type="bibr">1</xref>]. The key to managing this public health crisis has been vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Several vaccines with a variety of platforms have been approved for use worldwide, including inactivated viral vector, nucleoside-modified mRNA, and recombinant-expressed protein vaccines [<xref rid="B2-vaccines-12-01312" ref-type="bibr">2</xref>]. As of August 2024, over 13.6 billion vaccine doses have been administered across the world [<xref rid="B1-vaccines-12-01312" ref-type="bibr">1</xref>]. However, there are still sparse data regarding the dynamics of the antibody-mediated immune response to COVID-19 vaccines, especially the intensity and duration of antibodies. There are modest data regarding protective SARS-CoV-2 immunoglobulin G (IgG) levels in immunocompromised populations originally excluded from clinical trials, such as transplant recipients (TR) and hemodialysis patients (HD) [<xref rid="B3-vaccines-12-01312" ref-type="bibr">3</xref>,<xref rid="B4-vaccines-12-01312" ref-type="bibr">4</xref>]. This was particularly true in many countries outside of the United States and Europe, where vaccine supplies varied in terms of availability, preparations, and delivery logistics [<xref rid="B5-vaccines-12-01312" ref-type="bibr">5</xref>].</p><p>Antibodies that bind to the SARS-CoV-2 spike protein receptor binding domain (RBD), arising from either infection or vaccination, are considered a surrogate of immune protection [<xref rid="B6-vaccines-12-01312" ref-type="bibr">6</xref>,<xref rid="B7-vaccines-12-01312" ref-type="bibr">7</xref>,<xref rid="B8-vaccines-12-01312" ref-type="bibr">8</xref>]. The vaccination results in SARS-CoV-2 anti-spike (anti-S) protein receptor-binding domain (S-RBD) antibodies demonstrated seroconversion rates of 81% in hemodialysis (HD) patients with prior infection and 77% in those without [<xref rid="B9-vaccines-12-01312" ref-type="bibr">9</xref>]. However, studies suggest a substantial decrease in anti-S SARS-CoV-2 immunoglobulin G (IgG) titers three months after infection in patients with chronic kidney disease [<xref rid="B10-vaccines-12-01312" ref-type="bibr">10</xref>]. Data for non-SARS-CoV-2 vaccines (e.g., hepatitis B, influenza, Clostridium tetani, Corynebacterium diphtheriae)suggest that vaccine-induced IgG in patients with end-stage kidney disease can vary substantially with respect to neutralizing antibody titers and the duration of pathogen specific immunity [<xref rid="B3-vaccines-12-01312" ref-type="bibr">3</xref>,<xref rid="B10-vaccines-12-01312" ref-type="bibr">10</xref>,<xref rid="B11-vaccines-12-01312" ref-type="bibr">11</xref>,<xref rid="B12-vaccines-12-01312" ref-type="bibr">12</xref>,<xref rid="B13-vaccines-12-01312" ref-type="bibr">13</xref>].</p><p>Chronic kidney disease (CKD) significantly increases the risk and severity of COVID-19, especially among HD patients, who have increased morbidity and mortality from infection [<xref rid="B10-vaccines-12-01312" ref-type="bibr">10</xref>,<xref rid="B14-vaccines-12-01312" ref-type="bibr">14</xref>]. In England, patients on in-center HD experienced an 11.3% infection rate and a 23% fatality rate; far higher than that of age-matched, non-hemodialysis subjects [<xref rid="B15-vaccines-12-01312" ref-type="bibr">15</xref>]. Similarly, TR patients also face unique challenges in generating an effective antibody response to infections and vaccines [<xref rid="B16-vaccines-12-01312" ref-type="bibr">16</xref>]. One study from 2021 of SARS-CoV-2 mRNA vaccines from 2021 in TR reported that only 17% of subjects had increased SARS-CoV-2 anti-S IgG levels after a single vaccine dose [<xref rid="B12-vaccines-12-01312" ref-type="bibr">12</xref>,<xref rid="B16-vaccines-12-01312" ref-type="bibr">16</xref>], while 58% sustained low seroconversion rates even after a second [<xref rid="B16-vaccines-12-01312" ref-type="bibr">16</xref>,<xref rid="B17-vaccines-12-01312" ref-type="bibr">17</xref>] or third vaccine dose [<xref rid="B18-vaccines-12-01312" ref-type="bibr">18</xref>]. These low seroconversion rates may be due to the prolonged use of immunosuppressive medications, along with an increased prevalence of comorbidities such as diabetes and cardiovascular disease [<xref rid="B16-vaccines-12-01312" ref-type="bibr">16</xref>,<xref rid="B18-vaccines-12-01312" ref-type="bibr">18</xref>,<xref rid="B19-vaccines-12-01312" ref-type="bibr">19</xref>,<xref rid="B20-vaccines-12-01312" ref-type="bibr">20</xref>]. Low levels of anti-spike IgG following a third vaccine dose in kidney transplant recipients were associated with symptomatic breakthrough SARS-CoV-2 infections and hospitalizations. Specifically, low anti-RBD IgG levels were significantly correlated with hospitalization during the Omicron surge [<xref rid="B21-vaccines-12-01312" ref-type="bibr">21</xref>]. While more vaccine booster doses appear to improve outcomes such as disease severity, hospitalization, and mortality rates, HD [<xref rid="B22-vaccines-12-01312" ref-type="bibr">22</xref>] and TR [<xref rid="B21-vaccines-12-01312" ref-type="bibr">21</xref>,<xref rid="B23-vaccines-12-01312" ref-type="bibr">23</xref>,<xref rid="B24-vaccines-12-01312" ref-type="bibr">24</xref>,<xref rid="B25-vaccines-12-01312" ref-type="bibr">25</xref>] continue to experience high rates of breakthrough infections despite multiple doses of COVID-19 vaccines. Taken together, these findings suggest a persistent high risk of COVID-19 in CKD and TR despite vaccination.</p><p>The Dominican Republic (DR) has a substantial burden of chronic kidney disease, with more than 7080 individuals reported in 2023 [<xref rid="B26-vaccines-12-01312" ref-type="bibr">26</xref>]. Of these, approximately 5275 were undergoing dialysis, and 4083 were receiving hemodialysis [<xref rid="B26-vaccines-12-01312" ref-type="bibr">26</xref>]. Additionally, 500 individuals were awaiting a kidney transplant, while about 299 received a kidney transplant between 2019 and 2023 [<xref rid="B27-vaccines-12-01312" ref-type="bibr">27</xref>]. It is crucial to generate data on COVID-19 vaccine responses in HD and TR in the DR to understand how demographic, environmental, and healthcare factors influence vaccine efficacy, ultimately enhancing healthcare outcomes both locally and globally. The DR&#x02019;s national COVID-19 vaccination program began in February 2021, prioritizing individuals at high risk of infection and mortality, including HD and TR [<xref rid="B28-vaccines-12-01312" ref-type="bibr">28</xref>]. Three vaccine options&#x02014;BNT162b2 (Pfizer-BioNTech), AZD1222 (AstraZeneca&#x02014;Oxford), and CoronaVac (Sinovac)&#x02014;were made available [<xref rid="B29-vaccines-12-01312" ref-type="bibr">29</xref>]. By March 2024, approximately 15 million doses had been administered to an estimated population of 11 million individuals, with 68% of the population receiving at least one dose and 56% being fully vaccinated with two or more doses [<xref rid="B1-vaccines-12-01312" ref-type="bibr">1</xref>]. However, there are limited real-world or clinical trial data on vaccine responses to HD and TR patients in the DR. This is critical because real-world variation in vaccine responses may occur due to variations in local and population health that are particular to individual countries (e.g., vaccine type available, access, ease of reaching populations).</p><p>To generate data that might facilitate a better understanding of how to protect vulnerable populations in real-world circumstances, we measured the IgG anti-S and anti-N immune response to SARS-CoV-2 infection and vaccination in TR and HD patients in the Dominican Republic. We performed a secondary analysis of capillary blood samples collected from Dominican HD and TR patients via volumetric micro sampling (VAMS) obtained from a previously approved study conducted by Instituto Nacional de Coordinaci&#x000f3;n de Trasplante (INCORT). IgG levels against SARS-CoV-2 spike protein and S-RBD, induced by both infection and vaccination among TR, HD, and healthy control subjects (CO), were measured using multiplex analysis, allowing for simultaneous detection of antibodies directed at the S- and N-proteins of SARS-CoV-2 strains [<xref rid="B6-vaccines-12-01312" ref-type="bibr">6</xref>,<xref rid="B30-vaccines-12-01312" ref-type="bibr">30</xref>,<xref rid="B31-vaccines-12-01312" ref-type="bibr">31</xref>].</p></sec><sec id="sec2-vaccines-12-01312"><title>2. Materials and&#x000a0;Methods</title><sec id="sec2dot1-vaccines-12-01312"><title>2.1. Human Subjects Ethics&#x000a0;Statement</title><p>This is a secondary analysis of existing capillary blood samples and deidentified data previously obtained by the INCORT in the Dominican Republic. The protocol was approved by the National Health Bioethics Committee of the Dominican Republic (CONABIOS, the Spanish acronym) (INCORT.PI2020.004.01). The secondary analysis was approved by the Institutional Review Boards (IRB) at the University of Rochester Medical Center (IRB STUDY00006807). All research data were coded in compliance with the Department of Health and Human Services Regulations for the Protection of Human Subjects (45 CFR 46.101(b) (4)).</p></sec><sec id="sec2dot2-vaccines-12-01312"><title>2.2. Subject Data&#x000a0;Analysis</title><p>The INCORT parent study enrolled 70 subjects sourced from four hospitals that are part of the national registry of transplant recipients, as well as from the dialysis units of three national referral hospitals. Additionally, a control group was recruited at three COVID-19 vaccination clinics across Santo Domingo, DR. Medical personnel and study staff disseminated information and recruited patients into the parent study through phone calls, during in-person hemodialysis sessions, and via follow-up visits for transplant recipients.</p><p>The eligibility criteria included adults aged 18 years or older who were undergoing hemodialysis or were solid organ transplant recipients willing to receive a COVID-19 vaccine. The control group comprised individuals who reported the absence of comorbidities, including prevalent conditions such as hypertension, diabetes mellitus, cardiovascular disease, chronic respiratory disease, immunodeficiency, and degenerative and autoimmune diseases (<xref rid="vaccines-12-01312-f001" ref-type="fig">Figure 1</xref>). To establish a well-defined reference group for comparison with the two cohorts with histories of immunosuppression, dialysis, and organ transplantation, this study included a control group free from common medical conditions known to increase the risk of COVID-19 infection and severe illness [<xref rid="B32-vaccines-12-01312" ref-type="bibr">32</xref>].</p><p>This study excluded individuals who tested positive for COVID-19 via polymerase chain reaction (PCR) at enrollment or on day 0, as well as those who had received any prior dose of a COVID-19 vaccine. This focus on unvaccinated groups aimed to establish a homogeneous study population, enabling a comprehensive analysis of key variables within the unique context of dialysis, organ transplantation, and COVID-19 vaccination status. Secondary analysis also included data previously collected by INCORT via in-person interviews by the INCORT research staff based on a self-reported questionnaire including demographics, health status, and history of COVID-19 infection and vaccination. The specific data included age, sex, race, ethnicity, highest level of education achieved, current medication, vaccine dosage, and immunization history (Hepatitis B, influenza). For those with a history of SARS-CoV-2 infection, the data included the severity of COVID-19 symptoms, including hospitalization, intensive care, and mechanical ventilation needs. The clinical variables in the HD and TR cohorts included the duration and type of dialysis access, time since transplantation, history of organ rejection, and details of both induction and current immunosuppression therapy. The clinical variables are summarized in (<xref rid="app1-vaccines-12-01312" ref-type="app">Tables S1&#x02013;S3</xref>). We utilized this comprehensive collection of variables in generalized linear modeling to enable a nuanced analysis of the complex interactions among organ transplantation, dialysis, COVID-19 infection, vaccination status, and other health factors within the study cohort. The cohorts&#x02019; demographics, infection, and vaccination status are summarized in (<xref rid="vaccines-12-01312-t001" ref-type="table">Table 1</xref> and <xref rid="vaccines-12-01312-t002" ref-type="table">Table 2</xref>).</p></sec><sec id="sec2dot3-vaccines-12-01312"><title>2.3. Sample&#x000a0;Collection</title><p>The secondary analysis included 271 volumetric absorptive microsampling (VAMS) capillary blood samples previously obtained from 70 subjects prior to SARS-CoV-2 vaccination and obtained after receiving at least one dose of either the BNT162b2 (Pfizer-BionTech) mRNA or CoronaVac (Sinovac) inactivated virus COVID-19 vaccine. This included both homologous and heterologous boosters, with the choice of vaccine determined by adherence to the Dominican Republic national guidelines for COVID-19 vaccination [<xref rid="B28-vaccines-12-01312" ref-type="bibr">28</xref>]. Heterologous boosters involve using a different vaccine for the booster dose, while homologous boosters use the same vaccine as the primary vaccination. The study population included three cohorts, each consisting of transplant recipients (TR), hemodialysis patients (HD), and healthy controls (CO). Each cohort was additionally stratified by subjects with a reported history of infection with, or testing positive for, SARS-CoV-2 infection, and those without this history. Samples previously banked by the INCORT in the Dominican Republic were sent to the University of Rochester Medical Center analysis of SARS-CoV-2 IgG-mediated immunity based on a mPlex assay [<xref rid="B6-vaccines-12-01312" ref-type="bibr">6</xref>,<xref rid="B30-vaccines-12-01312" ref-type="bibr">30</xref>,<xref rid="B31-vaccines-12-01312" ref-type="bibr">31</xref>].</p></sec><sec id="sec2dot4-vaccines-12-01312"><title>2.4. mPlex-CoV&#x000a0;Assay</title><p>The samples were batch-processed as previously described [<xref rid="B6-vaccines-12-01312" ref-type="bibr">6</xref>,<xref rid="B30-vaccines-12-01312" ref-type="bibr">30</xref>,<xref rid="B31-vaccines-12-01312" ref-type="bibr">31</xref>]. Antibodies were eluted from the VAMS swabs by soaking them in 200 <inline-formula><mml:math id="mm1" overflow="scroll"><mml:mrow><mml:mi mathvariant="sans-serif">&#x003bc;</mml:mi></mml:mrow></mml:math></inline-formula>L of extraction buffer (0.5% Tween 20, 1% BSA in PBS buffer) at 4 &#x000b0;C under gentle agitation overnight. The eluents were aliquoted into 100 <inline-formula><mml:math id="mm2" overflow="scroll"><mml:mrow><mml:mi mathvariant="sans-serif">&#x003bc;</mml:mi></mml:mrow></mml:math></inline-formula>L tubes and stored at 4 &#x000b0;C for the multiplex assay [<xref rid="B33-vaccines-12-01312" ref-type="bibr">33</xref>]. We used the mPlex-CoV multiplex assay to measure IgG concentrations directed against SARS-CoV-2 spike (S) and nucleocapsid (N) protein antigens from multiple viral variants [<xref rid="B6-vaccines-12-01312" ref-type="bibr">6</xref>,<xref rid="B30-vaccines-12-01312" ref-type="bibr">30</xref>,<xref rid="B31-vaccines-12-01312" ref-type="bibr">31</xref>]. The targets included recombinant, trimerized SARS-CoV-2 S- and N- proteins, along with recombinant S1, S2, and RBD domain proteins (SinoBio, Beijing, China). The proteins were coupled to magnetic microsphere beads (Luminex, Austin, TX, USA) at 40 pmole/106 beads using the xMAP<sup>&#x000ae;</sup> Antibody Coupling kit (Luminex, Austin, TX, USA). For the assay, 200 <inline-formula><mml:math id="mm3" overflow="scroll"><mml:mrow><mml:mi mathvariant="sans-serif">&#x003bc;</mml:mi></mml:mrow></mml:math></inline-formula>L of eluent from VAMS devices (diluted at 1:20) underwent further dilution at 1:50 (for the IgG assay), resulting in final sample dilutions of 1:1000 (IgG). A total of 50 <inline-formula><mml:math id="mm4" overflow="scroll"><mml:mrow><mml:mi mathvariant="sans-serif">&#x003bc;</mml:mi></mml:mrow></mml:math></inline-formula>L of diluted sample was added to duplicate wells of black, clear-bottomed 96-well plates (Microplate, GBO, Kremsm&#x000fc;nster, Austria), with 50 <inline-formula><mml:math id="mm5" overflow="scroll"><mml:mrow><mml:mi mathvariant="sans-serif">&#x003bc;</mml:mi></mml:mrow></mml:math></inline-formula>L of the mPlex-CoV bead panel added to each well. After washing, the bound IgG was detected using phycoerythrin-conjugated anti-human IgG (Southern Biotech, Birmingham, AL, USA, Cal No:2040-09, 2050-09), and the median fluorescence intensity (MFI) was read using a Luminex MagPix [<xref rid="B6-vaccines-12-01312" ref-type="bibr">6</xref>,<xref rid="B31-vaccines-12-01312" ref-type="bibr">31</xref>].</p></sec><sec id="sec2dot5-vaccines-12-01312"><title>2.5. Measurement of Hemoglobin (Hgb) and Adjustment of Antibody Concentration</title><p>We adjusted capillary blood IgG concentrations for plasma volume using Hgb measured from the VAMS eluent samples, as previously described [<xref rid="B33-vaccines-12-01312" ref-type="bibr">33</xref>]. Hematocrit was calculated from Hgb concentrations to adjust the measured SARS-CoV-2 IgG concentration to estimate serum IgG concentrations. Finally, the concentrations of specific SARS-CoV-2 S (S1, S2, RBB) and N IgG antibodies in each sample were estimated using standard IgG curves generated from positive pooled sera samples, as previously described [<xref rid="B6-vaccines-12-01312" ref-type="bibr">6</xref>,<xref rid="B31-vaccines-12-01312" ref-type="bibr">31</xref>].</p></sec><sec id="sec2dot6-vaccines-12-01312"><title>2.6. Statistical&#x000a0;Analysis</title><p>The participant characteristics were summarized using frequency distributions and summary statistics. Differences between study groups were assessed using either the Chi-square or Fisher&#x02019;s exact test for categorical variables. The non-parametric Kolmogorov&#x02013;Smirnov test was applied to assess whether the antibody levels were normally distributed across different sample batches. Generalized linear mixed effects modeling (GLMM) was used to assess the longitudinal anti-S, S1, S2, RBD, and anti-N SARS-CoV-2-specific IgG antibody response elicited by COVID-19 vaccination and infection over time; factors associated with changes in antibody concentrations; and differences between cohorts. Pearson&#x02019;s correlation coefficient was applied to assess the association between the responses of the different IgG antibodies and between cohorts.</p><p>We used binary logistic regression to examine the independent associations between predictors and the primary outcome, SARS-CoV-2 IgG antibodies [<xref rid="B34-vaccines-12-01312" ref-type="bibr">34</xref>]. We assessed multicollinearity by calculating Variance Inflation Factors (VIFs), with all predictors having VIF values below the threshold of 5. The goodness-of-fit of the GLMM models was examined using residual diagnostic plots. We developed distinct GLMMs to analyze the anti-S, anti-RBD, and anti-N IgG responses, ensuring that each model consistently included demographic variables, prior COVID-19 infection history, and vaccine-related factors such as vaccine type and number of doses. We fitted the models using the glmmTMB function in R, incorporating splines to more accurately capture significant changes at key points along the timeline. Statistical analysis was performed using the statistical analysis software R, version 3.5.1 (R Core Team, 2017). The significance level for all the tests was set to <italic toggle="yes">p</italic> &#x0003c; 0.05.</p></sec></sec><sec sec-type="results" id="sec3-vaccines-12-01312"><title>3. Results</title><sec id="sec3dot1-vaccines-12-01312"><title>3.1. Participant&#x000a0;Characteristics</title><p>The subject demographics are shown in <xref rid="vaccines-12-01312-t001" ref-type="table">Table 1</xref>, including 70 subjects distributed across three cohorts: control (<italic toggle="yes">n</italic> = 33, 59%), HD (<italic toggle="yes">n</italic> = 13, 18%), and TR (<italic toggle="yes">n</italic> = 24, 23%). There were no statistically significant differences in age or gender between the cohorts (<italic toggle="yes">p</italic> = 0.150), although there was a slightly higher percentage of male subjects (57%) compared to females across the HD and TR cohorts, but not in the CO cohort. The majority of the subjects identified as Black and Hispanic or Latino (<italic toggle="yes">p</italic> &#x0003c; 0.001). This is consistent with the demographics in the Dominican Republic, where 74% of Dominicans identify as mixed race [<xref rid="B35-vaccines-12-01312" ref-type="bibr">35</xref>]. The DR distinguishes between race and ethnicity in a way that reflects the country&#x02019;s unique historical and social context, unlike in the US, where race and ethnicity are often treated as separate categories. However, it is important to note that the questionnaire used in our study did not include mixed race as an option, which may have influenced respondents who identified with this category to choose Black as their predominant race.</p><p>With respect to education, the TR cohort had a larger proportion of subjects with higher educational levels (<italic toggle="yes">p</italic> &#x0003c; 0.001). As expected, subjects without underlying conditions were primarily in the CO group, while those with at least one underlying medical condition were more evenly distributed across the cohorts. Additionally, 44% of the subjects reported a history of COVID-19 infection or a positive test before the initial sample and vaccination (<xref rid="vaccines-12-01312-t001" ref-type="table">Table 1</xref>). The imbalance in recruitment between the cohorts resulted from challenges faced during INCORT recruitment. Initially, accelerated vaccination efforts prioritized high-risk groups, including hemodialysis and transplant recipients, making it difficult to find unvaccinated individuals.</p></sec><sec id="sec3dot2-vaccines-12-01312"><title>3.2. Vaccination Characteristics and Prior COVID-19&#x000a0;Status</title><p>We compared vaccine and previous infection characteristics across the three cohorts. (<xref rid="vaccines-12-01312-t002" ref-type="table">Table 2</xref>) We found significant differences in the number of vaccine doses (<italic toggle="yes">p</italic> &#x0003c; 0.001), with the TR cohort having the highest percentage of fully vaccinated individuals with one booster (42%). Although variation was present in vaccine type distribution between the groups, these differences did not reach statistical significance (<italic toggle="yes">p</italic> = 0.066). Similarly, differences in booster combinations with respect to the primary vaccine (homologous or heterologous) were also not statistically significant. In all cases, for heterologous vaccination, the initial vaccine administered was CoronaVac, with a subsequent BNT162b2 booster. Conversely, in the homologous group, the trend was use of both a BNT162b2 prime and booster (87.5%), with only one participant opting for CoronaVac (12.5%).</p><p>Regarding previous COVID-19 infection, while the TR cohort had a higher percentage of previously positive COVID infection or positive PCR tests (63%) compared to HD (46%) and CO (30%), these results did not reach statistical significance. Similarly, there was no statistically significant difference between cohorts in COVID-19 positivity during this study, though most data were not reported, as only 21.43% of the subjects reported being aware of testing positive prior to the study.</p></sec><sec id="sec3dot3-vaccines-12-01312"><title>3.3. Generalized Linear&#x000a0;Modeling</title><p>To determine the association between SARS-CoV-2 anti-S antibody concentrations and other variables, we first performed a simple linear regression analysis to aid in variable selection. We found that age (<italic toggle="yes">p</italic> = 0.001), the male sex (<italic toggle="yes">p</italic> = 0.043), years of education (<italic toggle="yes">p</italic> = 0.0003), and the number of medical conditions reported (<italic toggle="yes">p</italic> = 0.064) had significant positive associations with SARS-CoV-2 anti-S IgG concentrations across all sampling time points.</p><p>Subsequently, we conducted a generalized linear model analysis, including variables that showed a positive association (<italic toggle="yes">p</italic> &#x0003c; 0.100) with SARS-CoV-2 anti-S IgG in the simple linear regression analysis (see <xref rid="vaccines-12-01312-t003" ref-type="table">Table 3</xref> for <inline-formula><mml:math id="mm6" overflow="scroll"><mml:mrow><mml:mi>&#x003b2;</mml:mi></mml:mrow></mml:math></inline-formula> values, 95% confidence intervals, and <italic toggle="yes">p</italic>-values). COVID-19 infection before the first vaccine was associated with increased anti-S IgG levels (<italic toggle="yes">p</italic> = 0.014). Similarly, receiving CoronaVac as the first vaccine dose (<italic toggle="yes">p</italic> &#x0003c; 0.001) and the number of doses received played a significant role, showing a positive association with elevated anti-S IgG levels (<italic toggle="yes">p</italic> = 0.008). Furthermore, receiving a homologous booster schedule was significantly associated with higher anti-S IgG levels (<italic toggle="yes">p</italic> = 0.014). As noted above, the homologous vaccination group predominantly received BNT162b2 for both the initial vaccination and the booster (<xref rid="vaccines-12-01312-t002" ref-type="table">Table 2</xref>), while the heterologous group received CoronaVac followed by a BNT162b2 booster. Heterologous boosters enhance immunogenicity, broaden protection against variants, improve antibody responses, and boost T-cell immunity, especially in transplant recipients [<xref rid="B36-vaccines-12-01312" ref-type="bibr">36</xref>,<xref rid="B37-vaccines-12-01312" ref-type="bibr">37</xref>]. This approach has been shown to provide extended protection beyond antibodies, potentially offering longer-lasting defense against SARS-CoV-2 with fewer adverse effects [<xref rid="B37-vaccines-12-01312" ref-type="bibr">37</xref>].</p><p>Samples collected 14 and 30 days after the second dose, as well as six months after the final dose (time points 3&#x02013;5), shoedw statistically significant elevations in SARS-CoV-2 anti-S IgG levels of 0.63 Log ng/mL (95% CI: 0.17&#x02013;1.10; <italic toggle="yes">p</italic> = 0.008), 0.54 Log ng/mL (95% CI: 0.10&#x02013;0.98) (<italic toggle="yes">p</italic> = 0.018), and 0.90 Log ng/mL (95% CI: 0.43&#x02013;1.4), respectively. As anticipated, these results suggest that later time points are associated with higher SARS-CoV-2 anti-S IgG levels compared to earlier time points. Lastly, the HD cohort had a greater association with higher SARS-CoV-2 anti-S IgG levels (<inline-formula><mml:math id="mm7" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>&#x003b2;</mml:mi><mml:mo>=</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> 1.3, 95% CI: &#x02212;0.13&#x02013;2.80) <italic toggle="yes">p</italic> = 0.073) across all time points when compared with the other two groups.</p></sec><sec id="sec3dot4-vaccines-12-01312"><title>3.4. Time Varying Anti-SARS-CoV-2 IgG&#x000a0;Response</title><p>We evaluated the development of the anti-SARS-CoV-2 spike IgG antibody resulting from either SARS-CoV-2 infection and/or vaccination. IgG concentrations were estimated against the original Wuhan variant SARS-CoV-2 full S protein and subunits (S1, S2, RBD) before and after the administration of either BNT162b2 or CoronaVac vaccines (<xref rid="vaccines-12-01312-f002" ref-type="fig">Figure 2</xref>). As hypothesized, there was a strong positive correlation between concentrations of anti-spike SARS-CoV-2 IgG and both anti-S2 IgG and anti-RBD IgG across all time points. While the association between increased anti-S IgG and anti-RBD IgG was more robust (R = 0.92) (<xref rid="app1-vaccines-12-01312" ref-type="app">Supplementary Figure S1</xref>), a strong correlation was found with anti-S2 IgG levels (R = 0.86) (<xref rid="app1-vaccines-12-01312" ref-type="app">Supplementary Figure S2</xref>). Anti-S2 IgGs have been reported to correlate with viral neutralization [<xref rid="B38-vaccines-12-01312" ref-type="bibr">38</xref>]. Furthermore, the concentrations of SARS-CoV-2 IgG against the S-RBD and S2 subunits also exhibited a statistically significant correlation (R = 0.81) (<xref rid="app1-vaccines-12-01312" ref-type="app">Supplementary Figure S3</xref>).</p><p>We observed statistically significant changes in anti-S IgG antibody levels (<italic toggle="yes">p</italic> = 0.028) across all time points after adjusting for the variables included in the GLMM (<xref rid="vaccines-12-01312-t003" ref-type="table">Table 3</xref>). The most pronounced differences occurred on day 130 (<italic toggle="yes">p</italic> &#x0003c; 0.001), regardless of the cohort. Notably, the HD group (4.08 &#x000b1; 0.587 log ng/mL) and the CO group (3.82 &#x000b1; 0.717 log ng/mL) exhibited higher antibody concentrations compared to the TR group (3.79 &#x000b1; 0.859 log ng/mL). Statistically significant differences were also noted in anti-S-RBD IgG antibody concentrations (<italic toggle="yes">p</italic> = 0.041), with higher levels in the HD (4.01 &#x000b1; 0.566 log ng/mL) and CO groups (3.88 &#x000b1; 0.690 log ng/mL) compared to the TR group (3.73 &#x000b1; 0.830 log ng/mL). Additionally, differences were found in anti-S2 IgG antibody concentrations (<italic toggle="yes">p</italic> = 0.006) between the HD group (3.11 &#x000b1; 0.447 log ng/mL) and CO group (2.86 log &#x000b1; 0.553 log ng/mL), both greater than the TR group (2.84 &#x000b1; 0.778 log ng/mL) by a slight margin.</p><p>As shown in <xref rid="vaccines-12-01312-f002" ref-type="fig">Figure 2</xref>, in the CO group, anti-S IgG levels increases to &#x0223c;4 log ng/mL by day 50, remaining steady through day 300, with anti-RBD IgG following a similar pattern at lower levels. In contrast, anti-S IgG in the HD group shows a steady increase to &#x0223c;5 log ng/mL by day 300, with anti-RBD also rising above 5 log ng/mL, while anti-S2 remained stable at &#x0223c;3 log ng/mL. The TR group started with lower anti-S and anti-RBD IgG levels, but both increased significantly over time to &#x0223c;5 log ng/mL by day 300, and anti-S2 rose to just below &#x0223c;3 log ng/mL. These results suggest that while the antibody response in the CO group stabilized, the HD and TR groups experienced a delayed but continuous increase in SARS-CoV-2 S IgG antibody concentration over time, indicating differences in immune response dynamics between the groups.</p></sec><sec id="sec3dot5-vaccines-12-01312"><title>3.5. SARS-CoV-2 Anti-Spike and Anti-Nucleocapsid IgG&#x000a0;Responses</title><p>We next assessed immunologic evidence of SARS-CoV-2 infection and vaccination during the study period among the three cohorts by measuring the levels of anti-S, anti-RBD, and anti-N IgG against the SARS-CoV-2 Wuhan variant (<xref rid="vaccines-12-01312-f003" ref-type="fig">Figure 3</xref>). Others have reported that for the general population, the anti-S IgGs peak between 22 and 28 days after infection or vaccination [<xref rid="B39-vaccines-12-01312" ref-type="bibr">39</xref>], maintaining levels that correlate with viral neutralization up to 180 days from the peak response and showing a modest decrease over time [<xref rid="B40-vaccines-12-01312" ref-type="bibr">40</xref>]. We hypothesized that we would observe blunted responses in the HD and TR populations, anticipating earlier and accelerated declines in peak levels of anti-S and anti-RBD IgGs compared to the CO group.</p><p>After receiving two vaccine doses (36.6 &#x000b1; 34.1 days), a total of 244 samples from the CO (<italic toggle="yes">n</italic> = 93), HD (<italic toggle="yes">n</italic> = 37), and TR (<italic toggle="yes">n</italic> = 114) groups were analyzed. Our analysis showed statistically significant differences in both anti-S and anti-RBD IgG levels between CO and HD (<italic toggle="yes">p</italic> &#x0003c; 0.010), as well as between CO and TR (<italic toggle="yes">p</italic> &#x0003c; 0.050) from day 0 to day 130 after the first dose. The CO group exhibited an increase in both anti-S and anti-RBD IgG levels, beginning on day 25 and peaking at day 50 (<italic toggle="yes">p</italic> &#x0003c; 0.030). Similarly, the HD group showed an increase in both anti-S IgG levels (1.416 log ng/mL) and anti-N IgG levels (1.01712 log ng/mL), with a moderate correlation (R = 0.63) (<xref rid="app1-vaccines-12-01312" ref-type="app">Supplemental Figure S4</xref>). Comparable trends were observed in the TR group (R = 0.64), but the anti-S IgG antibody levels in the TR group were significantly lower compared to the CO group (<italic toggle="yes">p</italic> &#x0003c; 0.050) and the HD group (<italic toggle="yes">p</italic> &#x0003c; 0.030). This observation in TR aligns with existing literature highlighting a diminished vaccine immune response in these immunosuppressed individuals [<xref rid="B41-vaccines-12-01312" ref-type="bibr">41</xref>].</p><p>The extended follow-up period in the HD group, and differences in the number of doses between groups, may contribute to the sustained increase in anti-S IgG. A significant proportion (79%, <italic toggle="yes">p</italic> &#x0003c; 0.001) of the HD group received two or more doses, which was slightly lower than the control group&#x02019;s rate (93%). Additionally, 23% of the HD group received booster doses, compared to 9% in the CO group. Compared to the CO group, the HD cohort had weaker and faster-declining immune responses to the standard two-dose mRNA COVID-19 vaccines [<xref rid="B10-vaccines-12-01312" ref-type="bibr">10</xref>,<xref rid="B22-vaccines-12-01312" ref-type="bibr">22</xref>]. While strategies like adjusting vaccine doses and timing are being studied, emerging variants have led to recommendations of multiple boosters, as well as bivalent vaccines targeting both the original strain and emerging variants of concern (e.g., omicron) [<xref rid="B42-vaccines-12-01312" ref-type="bibr">42</xref>]. It is essential to emphasize that 21% of the HD group, in contrast to 7% of the CO group, are excluded from <xref rid="vaccines-12-01312-f003" ref-type="fig">Figure 3</xref>, as they received only one vaccine dose (see <xref rid="vaccines-12-01312-t002" ref-type="table">Table 2</xref>).</p><p>The antibody trends for anti-S and anti-RBD IgG varied across groups over time. In CO, anti-S antibodies peaked on day 35 (<italic toggle="yes">p</italic> &#x0003c; 0.001), and anti-RBD antibodies peaked on day 50 (<italic toggle="yes">p</italic> = 0.002), followed by stabilization. In contrast, both anti-S and anti-RBD IgG concentrations rose slowly in the TR group, peaking after &#x0223c;250 days (anti-S IgG: <italic toggle="yes">p</italic> = 0.006; anti-RBD IgG: <italic toggle="yes">p</italic> = 0.025). The HD group showed an initial increase in anti-RBD IgG levels, peaking around day 65 (<italic toggle="yes">p</italic> = 0.059), followed by consistently high levels throughout the study. The pattern of anti-RBD IgG observed in the TR and HD groups suggests that the increase is likely due to SARS-CoV-2 vaccination rather than reinfection. This is consistent with reports that anti-RBD IgG levels remain stable with reinfection but rise with vaccination [<xref rid="B43-vaccines-12-01312" ref-type="bibr">43</xref>]. This phenomenon of back boosting occurs when a subsequent vaccination or infection with a different strain of the virus enhances the immune response against previously encountered strains, and is facilitated by reactivation of memory B and T cells initially generated in response to earlier exposure to antigenically similar strains [<xref rid="B44-vaccines-12-01312" ref-type="bibr">44</xref>].</p><p>A comparative analysis of anti-N IgG concentrations showed distinct patterns in the HD and TR groups compared to the CO group. Although both TR and HD had consistently higher anti-N IgG levels than the CO group (<italic toggle="yes">p</italic> = 0.003), a later increase in anti-N IgG levels in the CO group points to potential new infections. In TR, anti-N IgG levels remained relatively constant. In the HD group, anti-N IgG levels peaked at &#x0223c;100 (<italic toggle="yes">p</italic> = 0.056), followed by a decline starting on day 130 (<italic toggle="yes">p</italic> = 0.017). In contrast, the CO group had consistently low anti-N IgG levels until day 200, after which a significant increase was observed (<italic toggle="yes">p</italic> = 0.012). This rise in anti-N IgG in the CO group, coinciding with a decline in anti-S IgG, suggests potential new infections. This observation is consistent with existing literature showing that anti-N IgG antibodies usually peak around 100 days after symptom onset and can persist for 200&#x02013;550 days after infection [<xref rid="B43-vaccines-12-01312" ref-type="bibr">43</xref>]. Those without reinfection show early waning of anti-N IgG levels, while individuals with reinfection experience an increase in anti-N IgG levels (<italic toggle="yes">p</italic> &#x0003c; 0.0001). Vaccination does not significantly affect anti-N IgG levels over time (<italic toggle="yes">p</italic> = 0.649) [<xref rid="B43-vaccines-12-01312" ref-type="bibr">43</xref>]. In the next section, we explore prior infection and different vaccine types as potential factors influencing antibody dynamics post-SARS-CoV-2 vaccination and potential infections.</p></sec><sec id="sec3dot6-vaccines-12-01312"><title>3.6. SARS-CoV-2 Anti-Spike and Anti-Nucleocapsid IgG Response in Previously Infected and Non-Infected&#x000a0;Subjects</title><p>To study the effects of prior SARS-CoV-2 infection on post-vaccination anti-S and anti-N IgG levels, we measured anti-S and anti-N IgG concentrations after the first vaccine dose (<xref rid="vaccines-12-01312-f004" ref-type="fig">Figure 4</xref>). We hypothesized that, compared to subjects without prior SARS-CoV-2 infection, subjects who had a history of prior SARS-CoV-2 infection would have higher and sustained anti-S IgG levels post-vaccination, regardless of their immunocompromised status. The GLMM analysis indicated that prior COVID-19 infection before the first study sample continued to alter subsequent anti-S IgG levels over time (<xref rid="vaccines-12-01312-t003" ref-type="table">Table 3</xref>). As expected, the subjects who had acquired natural immunity from a previous COVID-19 infection showed significantly higher levels of anti-S IgG post-vaccination compared to those without a history of infection. This trend was observed across all groups, with CO and HD displaying more pronounced differences compared to TR. In contrast, the anti-N IgG levels in previously infected patients overlapped with those of patients without prior infection across these groups.</p><p>When comparing responses based on prior infection status, significant differences were observed in the overall response based on anti-S IgG (<italic toggle="yes">p</italic> &#x0003c; 0.001) and anti-N IgG levels (<italic toggle="yes">p</italic> &#x0003c; 0.050). Notably, the overall response based on anti-S2 IgG levels was also significantly higher in patients with prior infection (<italic toggle="yes">p</italic> &#x0003c; 0.001). Among subjects with a history of COVID-19 infection, anti-S IgG levels were significantly higher in the HD group compared to the CO group (<italic toggle="yes">p</italic> &#x0003c; 0.010), though no significant differences were found when compared to the TR group (<italic toggle="yes">p</italic> &#x0003e; 0.050). Interestingly, anti-N IgG levels were significantly lower in the TR group compared to the CO group (<italic toggle="yes">p</italic> &#x0003c; 0.050), but no significant differences were observed between the CO and HD groups.</p><p>As we hypothesized, individuals with a history of prior COVID-19 infection had significantly higher initial anti-N IgG levels compared to those without a history (<italic toggle="yes">p</italic> = 0.014). In the CO and HD groups, the initial levels were &#x0223c;4.5 log ng/mL, while in the TR group, the levels were &#x0223c;3.5 log ng/mL. By day 100, these levels increased to 5 log ng/mL for the CO and HD groups and then stabilized to &#x0223c;4.5 log ng/mL through the end of the follow-up period, reflecting a sustained immune response. In contrast, the TR subjects had slightly lower levels, with minor fluctuations, stabilizing at &#x0223c;3.5 log ng/mL. The literature on anti-N IgG antibody levels following the CoronaVac vaccine provides valuable insights into the immune response elicited by inactivated virus vaccines. A study comparing anti-N levels found that naturally infected individuals had significantly higher anti-N IgG levels compared to those vaccinated with CoronaVac or BNT162b2 [<xref rid="B45-vaccines-12-01312" ref-type="bibr">45</xref>].</p></sec><sec id="sec3dot7-vaccines-12-01312"><title>3.7. SARS-CoV-2 Anti-Spike and Anti-Nucleocapsid IgG Responses and Vaccine&#x000a0;Type</title><p>We next analyzed qualitative anti-S and anti-N IgG responses to BNT162b2 and CoronaVac, which revealed significant overlap in anti-N IgG levels within the TR group but not in the CO and HD groups (<xref rid="vaccines-12-01312-f005" ref-type="fig">Figure 5</xref>). A key finding was that BNT162b2 resulted in higher anti-S IgG levels across the CO, HD, and TR groups, while CoronaVac was associated with higher anti-N IgG levels. However, no significant overall effect was observed based on the type of vaccine administered. Additionally, no significant interaction was found between prior infection and vaccine type for either anti-S or anti-N IgG levels.</p><p>A significant difference was found in anti-S IgG levels between cohorts vaccinated with CoronaVac and those with BNT162b2 (<italic toggle="yes">p</italic> &#x0003c; 0.050). Specifically, CoronaVac showed a significant impact on anti-S IgG responses between CO and HD groups (<italic toggle="yes">p</italic> &#x0003c; 0.050) and CO and TR groups (<italic toggle="yes">p</italic> &#x0003c; 0.010). Differences between the groups reveal that the CO group had the most stable anti-S IgG levels for both vaccines, with similar peak timings and gradual declines. BNT162b2 induced a stronger initial IgG response that declined over time in all the groups. CoronaVac showed a delayed but gradually increasing response in HD and TR, but not in CO. This variation suggests that underlying health conditions may influence the immune response in this population. Previous studies have shown that individuals vaccinated with the BNT162b2 vaccine had significantly higher neutralizing antibody titers compared to those who received the CoronaVac vaccine [<xref rid="B46-vaccines-12-01312" ref-type="bibr">46</xref>].</p><p>These effects were also exhibited in anti-N IgG levels when comparing the CO and HD groups (<italic toggle="yes">p</italic> &#x0003c; 0.050) and CO and TR groups (<italic toggle="yes">p</italic> &#x0003c; 0.001). Notably, CoronaVac elicited significantly higher anti-N IgG levels than BNT162b2 during the early stages of the immune response (0&#x02013;15 days, <italic toggle="yes">p</italic> &#x0003c; 0.050). However, the effects on anti-N IgG levels between 15 and 35 days did not reach statistical significance. In the HD and TR patients who received the CoronaVac vaccine, while anti-N levels initially increased, anti-S levels peaked on day 300 (HD) and day 100 (TR), and anti-N levels decreased. This pattern of initially high anti-N levels gradually decreasing, followed by an increase in anti-S levels, could suggest recent infection rather than a response solely to vaccination. It could also be due to the composition of the CoronaVac vaccine, as attenuated viral components can potentially induce an anti-N IgG response that may boost natural infection, and vice versa, or vaccination [<xref rid="B40-vaccines-12-01312" ref-type="bibr">40</xref>,<xref rid="B47-vaccines-12-01312" ref-type="bibr">47</xref>].</p><p>As previously described in the GLMM (<xref rid="vaccines-12-01312-t003" ref-type="table">Table 3</xref>), many factors could affect anti-S and anti-N IgG levels among the vaccinated subjects, including prior infection, number of doses, and time of sampling after vaccination. Anti-N antibody measures might serve as a tool to identify past and current COVID-19 infections among a population vaccinated with mRNA-based vaccines. However, vaccination with CoronaVac may not be as effective, as attenuated virus vaccines could potentially elicit an anti-N response in addition to inducing antibodies against S protein. This could boost the immune response to natural infection or other types of vaccination [<xref rid="B40-vaccines-12-01312" ref-type="bibr">40</xref>].</p></sec></sec><sec sec-type="discussion" id="sec4-vaccines-12-01312"><title>4. Discussion</title><p>The COVID-19 pandemic profoundly impacted global health. Early vaccine trials excluded HD and TR [<xref rid="B3-vaccines-12-01312" ref-type="bibr">3</xref>,<xref rid="B4-vaccines-12-01312" ref-type="bibr">4</xref>]. Understanding the humoral response to SARS-CoV-2 infection and vaccination, along with vaccine and population-specific factors, is crucial for protecting vulnerable groups. While studies have reported immune responses in TR and HD after SARS-CoV-2 vaccination, data on mRNA and inactivated vaccines remain limited, especially outside the U.S. and Europe. Our study analyzed the antibody response to COVID-19 vaccination in 70 subjects across 3 cohorts: HD, TR, and CO, focusing on the BNT162b2 and CoronaVac vaccines (<xref rid="vaccines-12-01312-f001" ref-type="fig">Figure 1</xref>). We applied mixed-effects modeling to assess variability in anti-S, anti-RBD, and anti-N IgG antibodies, focusing on response magnitude and duration. This approach provided more accurate estimates by accounting for both fixed effects (e.g., baseline subject characteristics) and random effects (e.g., cohort variability).</p><p>Our analysis of anti-S IgG, anti-RBD, and anti-N responses across different cohorts revealed significant differences, particularly within the first 130 days post-vaccination (<xref rid="vaccines-12-01312-f003" ref-type="fig">Figure 3</xref>). While the CO group experienced an early peak in both anti-S and anti-RBD IgG, followed by stabilization, the TR group had a similar pattern, but with a slower rise and later peaks. The HD group, however, showed fluctuating levels, with an initial peak, a subsequent decline, and a later rise. Overall, the CO group maintained more stable antibody levels compared to the fluctuating levels observed in the HD and TR groups. The fluctuations in the HD and TR groups suggest that changes in anti-S and anti-RBD IgG levels are likely attributable to vaccination rather than reinfection. This finding supports the existing literature, which indicates that anti-RBD IgG levels generally remain stable with reinfection but increase with vaccination. This &#x0201c;back-boosting&#x0201d; effect occurs when additional vaccinations or exposure to different virus strains enhance the immune response by reactivating memory B and T cells.</p><p>Furthermore, the differences in anti-N IgG antibody responses between HD and TR compared to CO suggest that the CO group might have encountered new infections (<xref rid="vaccines-12-01312-f003" ref-type="fig">Figure 3</xref>). The increase in anti-N IgG levels observed towards the end of the study, along with the decline in anti-S IgG levels from their peak on day 35, supports this possibility. The peak and subsequent decline in anti-S IgG levels observed in the CO cohort are consistent with established patterns of antibody kinetics in the general population [<xref rid="B40-vaccines-12-01312" ref-type="bibr">40</xref>]. The rise in anti-N levels on day 200, despite the decline in anti-S IgG, suggests a complex immunological response, possibly influenced by subsequent virus exposure. This aligns with findings in healthy individuals, where anti-N IgG peaks around 100 days post-infection and persists for months, with reinfection causing significant increases and vaccination having minimal impact over time [<xref rid="B43-vaccines-12-01312" ref-type="bibr">43</xref>].</p><p>The comparative analysis of anti-N levels also highlighted differences between the immunocompromised cohorts, with both the TR and HD groups showing higher concentrations than the CO group. However, the smaller increase in both anti-S and anti-N IgG levels in the TR group compared to the HD group may reflect the impact of immunosuppressive therapy on immune responses to infection and vaccination [<xref rid="B41-vaccines-12-01312" ref-type="bibr">41</xref>]. This observation aligns with existing literature suggesting that immunosuppressed individuals often exhibit a diminished vaccine-induced immune response [<xref rid="B41-vaccines-12-01312" ref-type="bibr">41</xref>]. These findings highlight the variability in immune responses across different patient groups and emphasize the need for vaccination strategies and monitoring approaches to address each group&#x02019;s distinct immunological profile.</p><p>The GLMM analysis revealed that prior SARS-CoV-2 infection had a significant impact on anti-S IgG levels post-vaccination across all cohorts. Temporal variations in antibody peaks indicate that the individuals with prior infection tended to reach peak antibody levels earlier than those without a history of infection (<xref rid="vaccines-12-01312-f004" ref-type="fig">Figure 4</xref>). The differences between the study groups revealed notable findings. In the HD group, prior infection significantly impacted both anti-S and anti-RBD early responses, resulting in higher anti-S IgG levels compared to the CO and TR groups. Although the CO and TR groups also showed elevated anti-S IgG levels in those with prior infection, their antibody concentrations displayed more variable peaks and fluctuations.</p><p>Our analysis indicates that individuals with a history of SARS-CoV-2 infection exhibited higher baseline anti-N levels and a significant increase over time. This outcome supports the understanding that individuals with prior infections have higher initial anti-N levels, as this is a key target of the immune response. Natural infection also appears to boost these levels more effectively than vaccination alone. Interestingly, while anti-N levels in the TR and CO groups decreased over time, the HD group maintained relatively stable levels. Specifically, the CO group, which showed higher anti-N levels compared to the HD and TR groups, likely represents those with more recent infections. Conversely, by day 100, both HD and TR groups, which were COVID-negative during the study, exhibited an increase in anti-N levels. This could suggest new infections or heightened immune responses in these groups. Additionally, individuals without prior infection in the HD and TR groups showed rising anti-N levels after day 100, whereas the CO group had stable anti-N levels, suggesting a more stable immune response and fewer new infections. This highlights the significant impact of prior infection on both the timing and magnitude of the anti-S IgG response across all cohorts.</p><p>Vaccine type also had a significant effect on the SARS-CoV-2 anti-S and anti-RBD IgG antibody responses, indicating that both the BNT162b2 and CoronaVac vaccines elicited robust humoral responses in all three cohorts. These responses were more pronounced after two doses and four weeks post-vaccination (<xref rid="vaccines-12-01312-f005" ref-type="fig">Figure 5</xref>). BNT162b2 elicited higher anti-S and anti-RBD IgG levels at all time points in both the CO and TR groups compared to CoronaVac. This pattern did not hold for the HD group, where BNT162b2 maintained higher antibody levels up to day 100, after which they declined. Meanwhile, CoronaVac began to increase, eventually surpassing BNT162b2 by day 250. When comparing vaccine types and the anti-S and anti-RBD antibody responses between the cohorts, it was evident that the CO group showed the most stable and consistent antibody levels for both vaccines, with similar peak timings and gradual declines. The HD group exhibited a delayed peak for BNT162b2 and more fluctuations for CoronaVac, suggesting a variable immune response that was potentially influenced by the underlying health conditions [<xref rid="B46-vaccines-12-01312" ref-type="bibr">46</xref>]. The TR group demonstrated the greatest variability, with significant fluctuations in antibody levels for both vaccines, indicating an even more inconsistent immune response that was likely due to immunosuppressive treatments or other factors related to transplantation.</p><p>Vaccine type also had a significant effect on the anti-N IgG response, although BNT162b2 and CoronaVac both target the spike protein rather than the nucleocapsid protein (<xref rid="vaccines-12-01312-f005" ref-type="fig">Figure 5</xref>). However, CoronaVac is an inactivated virus vaccine that may also stimulate the production of nucleocapsid antigens, likely explaining the higher levels of anti-N IgG antibodies seen in its recipients compared to those who received BNT162b2 [<xref rid="B40-vaccines-12-01312" ref-type="bibr">40</xref>,<xref rid="B47-vaccines-12-01312" ref-type="bibr">47</xref>]. This may reflect differences in vaccine-induced immunity compared to natural infection. Furthermore, significant interaction effects were observed in the HD and TR groups between prior SARS-CoV-2 infection and vaccine type. Both vaccines induced higher antibody levels in individuals with a previous infection at baseline in these groups. These findings highlight the complex interplay between patient-specific characteristics, prior infection status, and vaccine type in shaping the immune response. The combined effects of the two vaccines in heterologous boosters could result in complex immune responses that are distinct from those observed with homologous booster doses. However, our ability to assess the specific effects of each booster type is limited, primarily because the majority of the subjects received a heterologous combination of CoronaVac followed by BNT162b2 vaccines. As a result, isolating the effects of each individual booster has proven difficult due to a lack of sufficient data. Specifically, our study lacks an adequate sample size that received a homogeneous vaccination, which is essential for conducting a comparative analysis.</p><p>Additionally, our study has several other limitations, the most significant being the small sample size. Recruitment was constrained by the rapid vaccination rollout in the Dominican Republic, making it difficult to enroll unvaccinated subjects, especially among immunocompromised groups who were prioritized for vaccination. Vaccine hesitancy among hemodialysis patients, likely due to their deteriorating health, further reduced the sample size. Additionally, age differences between groups complicated our ability to control for confounding factors, making it hard to separate age effects from group effects. Lastly, a longer follow-up period is needed to assess long-term vaccine responses and the impact of different dosing schedules.</p><p>The study population was demographically diverse in age, balanced in sex, and primarily Hispanic or Latino, with a significant Black representation, reflecting the Dominican Republic&#x02019;s COVID-19 context. The lower vaccination rate in the CO group compared to the two immunocompromised groups aligns with previous research indicating barriers or delays, which may be related to concerns about vaccine novelty, side effects, or a perceived lower risk of COVID-19 among healthy and younger individuals [<xref rid="B48-vaccines-12-01312" ref-type="bibr">48</xref>]. This finding mirrors global trends of vaccine hesitancy among individuals with chronic health conditions, particularly in HD, regarding the uptake of second and booster doses [<xref rid="B49-vaccines-12-01312" ref-type="bibr">49</xref>]. The reluctance in HD may stem from less-informed health beliefs, an underestimated risk of COVID-19, concerns about vaccine safety, or weakened patient&#x02013;clinician relationships [<xref rid="B49-vaccines-12-01312" ref-type="bibr">49</xref>]. However, patients are more likely to become vaccinated if recommended by their nephrologist [<xref rid="B49-vaccines-12-01312" ref-type="bibr">49</xref>]. On the other hand, 91.7% of the TR patients received two or more doses. This high vaccination rate may be attributed to the higher education levels observed in this group, concerns about their clinical history, and a lower initial vaccine response [<xref rid="B18-vaccines-12-01312" ref-type="bibr">18</xref>]. Higher education often leads to better adherence to preventive measures and more proactive healthcare, which could positively influence their COVID-19 outcomes [<xref rid="B50-vaccines-12-01312" ref-type="bibr">50</xref>].</p><p>Overall, our results underscore the variability in immune responses to SARS-CoV-2 among different patient groups and highlight the critical role of vaccine type in modulating these responses, particularly the interactions of anti-S IgG between the HD, TR, and CO groups. This variability has important implications for real-world clinical applications, guiding vaccine selection for immunocompromised populations to recommend vaccines that elicit stronger immune defenses. Additionally, routine monitoring of anti-N IgG levels can help to assess new infections and vaccine efficacy, prompting timely booster doses for those at higher risk. Public health messaging can be enhanced by educating patients about the protective benefits of specific vaccines, while policymakers can prioritize distribution strategies based on these findings. Ultimately, continued research into these immunological responses will inform future vaccine designs, optimizing protection against SARS-CoV-2 variants and improving overall vaccination outcomes, especially for vulnerable populations.</p></sec><sec sec-type="conclusions" id="sec5-vaccines-12-01312"><title>5. Conclusions</title><p>The CO group had an early peak with stable anti-S and anti-RBD antibodies; the TR group showed a gradually lower increase; and the HD group exhibited fluctuating but generally high levels, likely due to back-boosting effects. However, the elevated anti-N IgG after a decline in anti-S suggests recent infection rather than vaccine response. Prior SARS-CoV-2 infection led to an early peak and higher anti-S IgG post-vaccination in all groups, but anti-N IgG levels were similar to those without prior infection. BNT162b2 was linked to higher anti-S IgG levels, while CoronaVac led to higher anti-N IgG levels. This international research collaboration identified vaccine-related factors influencing anti-S, anti-RBD, and anti-N IgG levels in HD and TR, offering insights to enhance public health strategies for protecting vulnerable populations.</p></sec></body><back><ack><title>Acknowledgments</title><p>We extend our deepest gratitude to the Instituto Nacional de Coordinaci&#x000f3;n de Trasplante (INCORT) and its esteemed team, particularly FernandoMorales Billini and Cesar Zorrila, for their invaluable support and collaboration throughout this study. We also acknowledge the significant contributions of the study team, the administrative team, and the national network of hospitals within the transplant coordination program. Their efforts have been essential to the success of this research.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-vaccines-12-01312"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/vaccines12121312/s1">https://www.mdpi.com/article/10.3390/vaccines12121312/s1</uri>, Figure S1. Correlation of SARS-CoV-2 IgG anti-spike protein and anti-RBD subunit by cohort and measured days after first vaccine; Figure S2. Correlation of SARS-CoV-2 IgG anti-spike protein and anti-S2 subunit by cohort and measured days after first vaccine; Figure S3. Correlation of SARS-CoV-2 IgG anti-RBD and anti-S2 subunits by cohort and measured days after first vaccine; Figure S4. Correlation of SARS-CoV-2 IgG anti-spike and anti-nucleocapsid proteins by cohort and measured days after first vaccine; Table S1. End-stage kidney disease and transplant cohort characteristics. This table presents the results of a statistical comparison of clinical characteristics between hemodialysis patients (<italic toggle="yes">n</italic> = 13) and transplant recipients (<italic toggle="yes">n</italic> = 24); Table S2. Hemodialysis characteristics. This table summarizes the hemodialysis characteristics of 13 subjects, focusing on access type and treatment duration; Table S3. Summary of transplant characteristics for 24 subjects.</p><supplementary-material id="vaccines-12-01312-s001" position="float" content-type="local-data"><media xlink:href="vaccines-12-01312-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, L.A.S., M.S.Z., K.F. and S.D.; methodology, M.S.Z., S.P.H., D.L. and K.F.; software, L.A.S. and D.L.; validation, L.A.S. and D.L.; formal analysis, L.A.S. and D.L.; investigation, L.A.S., S.M.K., Q.Z., E.A.G. and S.P.H.; resources, M.S.Z.; data curation, L.A.S. and D.L.; writing&#x02014;original draft preparation, L.A.S.; writing&#x02014;review and editing, M.S.Z., K.F., E.A.G. and S.D.; visualization, L.A.S., D.L. and M.S.Z.; supervision, K.F., M.S.Z. and S.D.; funding acquisition, M.S.Z. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>This is a secondary analysis of existing capillary blood samples and deidentified data previously obtained by the INCORT in the Dominican Republic. The parent study was conducted in accordance with the Declaration of Helsinki and previously approved by the National Health Bioethics Committee of the Dominican Republic (CONABIOS, the Spanish acronym) (INCORT.PI2020.004.01) for studies involving humans. The secondary analysis was approved by the Institutional Review Boards (IRB) at the University of Rochester Medical Center (IRB STUDY00006807). All research data were coded in compliance with the Department of Health and Human Services Regulations for the Protection of Human Subjects (45 CFR 46.101(b) (4)).</p></notes><notes><title>Informed Consent Statement</title><p>This research study involved a secondary analysis of existing capillary blood samples and deidentified data that were originally collected by the INCORT in the Dominican Republic. The initial research adhered to the Declaration of Helsinki and received approval from the National Health Bioethics Committee of the Dominican Republic (CONABIOS) under protocol INCORT.PI2020.004.01 for studies involving human participants.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The original data presented in this study, along with the R code used for analysis, are openly available at <uri>FigShare.com</uri> (DOI 10.60593/ur.d.27460125).</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.</p></notes><glossary><title>Abbreviations</title><p>The following abbreviations are used in this manuscript:
<array><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">CO</td><td align="left" valign="top" rowspan="1" colspan="1">Control group</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CONABIOS</td><td align="left" valign="top" rowspan="1" colspan="1">National Health Bioethics Committee of the Dominican Republic</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
</td><td align="left" valign="top" rowspan="1" colspan="1">(the Spanish acronym)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">COVID-19</td><td align="left" valign="top" rowspan="1" colspan="1">Coronavirus disease 2019</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DOAJ</td><td align="left" valign="top" rowspan="1" colspan="1">Directory of Open Access Journals</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ESRD</td><td align="left" valign="top" rowspan="1" colspan="1">End-Stage Renal Disease</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GLMM</td><td align="left" valign="top" rowspan="1" colspan="1">Generalized Linear Mixed Models</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HD</td><td align="left" valign="top" rowspan="1" colspan="1">Hemodialysis Patients</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hgb</td><td align="left" valign="top" rowspan="1" colspan="1">Hemoglobin</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IgG</td><td align="left" valign="top" rowspan="1" colspan="1">Immunoglobin G</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">INCORT</td><td align="left" valign="top" rowspan="1" colspan="1">Instituto Nacional de Coordinaci&#x000f3;n de Trasplante</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IRB</td><td align="left" valign="top" rowspan="1" colspan="1">Institutional Review Boards</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MDPI</td><td align="left" valign="top" rowspan="1" colspan="1">Multidisciplinary Digital Publishing Institute</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">mPlex-CoV</td><td align="left" valign="top" rowspan="1" colspan="1">Fluorescent Multiplex Assay</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">N</td><td align="left" valign="top" rowspan="1" colspan="1">Nucleocapsid</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PCR</td><td align="left" valign="top" rowspan="1" colspan="1">Polymerase Chain Reaction</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">RNA</td><td align="left" valign="top" rowspan="1" colspan="1">Ribonucleic acid</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">S</td><td align="left" valign="top" rowspan="1" colspan="1">Spike</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SARS-CoV-2</td><td align="left" valign="top" rowspan="1" colspan="1">Severe Acute Respiratory Syndrome Coronavirus 2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TR</td><td align="left" valign="top" rowspan="1" colspan="1">Transplant Recipients</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">VAMS</td><td align="left" valign="top" rowspan="1" colspan="1">Volumetric Micro Sampling</td></tr></tbody></array></p></glossary><ref-list><title>References</title><ref id="B1-vaccines-12-01312"><label>1.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group><article-title>WHO Caronavirus Dashboard</article-title><comment>Available online: <ext-link xlink:href="https://covid19.who.int/" ext-link-type="uri">https://covid19.who.int/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-10">(accessed on 10 September 2024)</date-in-citation></element-citation></ref><ref id="B2-vaccines-12-01312"><label>2.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group><article-title>Status of COVID-19 Vaccines Within WHO EUL/PQ Evaluation Process</article-title><year>2023</year><comment>Available online: <ext-link xlink:href="https://extranet.who.int/prequal/sites/default/files/document_files/Status_COVID_VAX_08AUgust2023.pdf" ext-link-type="uri">https://extranet.who.int/prequal/sites/default/files/document_files/Status_COVID_VAX_08AUgust2023.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-14">(accessed on 14 September 2024)</date-in-citation></element-citation></ref><ref id="B3-vaccines-12-01312"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Carr</surname><given-names>E.J.</given-names></name>
<name><surname>Kronbichler</surname><given-names>A.</given-names></name>
<name><surname>Graham-Brown</surname><given-names>M.</given-names></name>
<name><surname>Abra</surname><given-names>G.</given-names></name>
<name><surname>Argyropoulos</surname><given-names>C.</given-names></name>
<name><surname>Harper</surname><given-names>L.</given-names></name>
<name><surname>Lerma</surname><given-names>E.V.</given-names></name>
<name><surname>Suri</surname><given-names>R.S.</given-names></name>
<name><surname>Topf</surname><given-names>J.</given-names></name>
<name><surname>Willicombe</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Systematic Review of Early Immune Response to SARS-CoV-2 Vaccination Among Patients with Chronic Kidney Disease</article-title><source>Kidney Int. Rep.</source><year>2021</year><volume>6</volume><fpage>2292</fpage><lpage>2304</lpage><pub-id pub-id-type="doi">10.1016/j.ekir.2021.06.027</pub-id><pub-id pub-id-type="pmid">34250319</pub-id>
</element-citation></ref><ref id="B4-vaccines-12-01312"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Goffin</surname><given-names>E.</given-names></name>
<name><surname>Candellier</surname><given-names>A.</given-names></name>
<name><surname>Vart</surname><given-names>P.</given-names></name>
<name><surname>Noordzij</surname><given-names>M.</given-names></name>
<name><surname>Arnol</surname><given-names>M.</given-names></name>
<name><surname>Covic</surname><given-names>A.</given-names></name>
<name><surname>Lentini</surname><given-names>P.</given-names></name>
<name><surname>Malik</surname><given-names>S.</given-names></name>
<name><surname>Reichert</surname><given-names>L.J.</given-names></name>
<name><surname>Sever</surname><given-names>M.S.</given-names></name>
<etal/>
</person-group><article-title>COVID-19 related mortality in kidney transplant and hemodialysis patients: A comparative, prospective registry based study</article-title><source>Nephrol. Dial. Transplant.</source><year>2021</year><volume>36</volume><fpage>2094</fpage><lpage>2105</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfab200</pub-id><pub-id pub-id-type="pmid">34132811</pub-id>
</element-citation></ref><ref id="B5-vaccines-12-01312"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wijewickrama</surname><given-names>E.S.</given-names></name>
<name><surname>Abdul Hafidz</surname><given-names>M.I.</given-names></name>
<name><surname>Robinson</surname><given-names>B.M.</given-names></name>
<name><surname>Johnson</surname><given-names>D.W.</given-names></name>
<name><surname>Liew</surname><given-names>A.</given-names></name>
<name><surname>Dreyer</surname><given-names>G.</given-names></name>
<name><surname>Caskey</surname><given-names>F.J.</given-names></name>
<name><surname>Bello</surname><given-names>A.K.</given-names></name>
<name><surname>Zaidi</surname><given-names>D.</given-names></name>
<name><surname>Damster</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Availability and prioritisation of COVID-19 vaccines among patients with advanced chronic kidney disease and kidney failure during the height of the pandemic: A global survey by the International Society of Nephrology</article-title><source>BMJ Open</source><year>2022</year><volume>12</volume><fpage>e065112</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2022-065112</pub-id></element-citation></ref><ref id="B6-vaccines-12-01312"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cameron</surname><given-names>A.</given-names></name>
<name><surname>Porterfield</surname><given-names>C.A.</given-names></name>
<name><surname>Byron</surname><given-names>L.</given-names></name>
<name><surname>Wang</surname><given-names>C.</given-names></name>
<name><surname>Pearson</surname><given-names>Z.</given-names></name>
<name><surname>Bohrhunter</surname><given-names>J.L.</given-names></name>
<name><surname>Cardillo</surname><given-names>A.B.</given-names></name>
<name><surname>Ryan-Muntz</surname><given-names>L.</given-names></name>
<name><surname>Sorensen</surname><given-names>R.A.</given-names></name>
<name><surname>Caserta</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>A Multiplex Microsphere IgG Assay for SARS-CoV-2 Using ACE2-Mediated Inhibition as a Surrogate for Neutralization</article-title><source>J. Clin. Microbiol.</source><year>2021</year><volume>59</volume><fpage>10-1128</fpage><pub-id pub-id-type="doi">10.1128/JCM.02489-20</pub-id></element-citation></ref><ref id="B7-vaccines-12-01312"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sasikala</surname><given-names>M.</given-names></name>
<name><surname>Shashidhar</surname><given-names>J.</given-names></name>
<name><surname>Deepika</surname><given-names>G.</given-names></name>
<name><surname>Ravikanth</surname><given-names>V.</given-names></name>
<name><surname>Krishna</surname><given-names>V.V.</given-names></name>
<name><surname>Sadhana</surname><given-names>Y.</given-names></name>
<name><surname>Pragathi</surname><given-names>K.</given-names></name>
<name><surname>Reddy</surname><given-names>D.N.</given-names></name>
</person-group><article-title>Immunological memory and neutralizing activity to a single dose of COVID-19 vaccine in previously infected individuals</article-title><source>Int. J. Infect. Dis.</source><year>2021</year><volume>108</volume><fpage>183</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2021.05.034</pub-id><pub-id pub-id-type="pmid">34022331</pub-id>
</element-citation></ref><ref id="B8-vaccines-12-01312"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wisnivesky</surname><given-names>J.P.</given-names></name>
<name><surname>Stone</surname><given-names>K.</given-names></name>
<name><surname>Bagiella</surname><given-names>E.</given-names></name>
<name><surname>Doernberg</surname><given-names>M.</given-names></name>
<name><surname>Mendu</surname><given-names>D.R.</given-names></name>
<name><surname>Lin</surname><given-names>J.J.</given-names></name>
<name><surname>Kale</surname><given-names>M.</given-names></name>
</person-group><article-title>Long-term Persistence of Neutralizing Antibodies to SARS-CoV-2 Following Infection</article-title><source>J. Gen. Intern. Med.</source><year>2021</year><volume>36</volume><fpage>3289</fpage><lpage>3291</lpage><pub-id pub-id-type="doi">10.1007/s11606-021-07057-0</pub-id><pub-id pub-id-type="pmid">34346008</pub-id>
</element-citation></ref><ref id="B9-vaccines-12-01312"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Anand</surname><given-names>S.</given-names></name>
<name><surname>Montez-Rath</surname><given-names>M.E.</given-names></name>
<name><surname>Han</surname><given-names>J.</given-names></name>
<name><surname>Garcia</surname><given-names>P.</given-names></name>
<name><surname>Cadden</surname><given-names>L.</given-names></name>
<name><surname>Hunsader</surname><given-names>P.</given-names></name>
<name><surname>Kerschmann</surname><given-names>R.</given-names></name>
<name><surname>Beyer</surname><given-names>P.</given-names></name>
<name><surname>Dittrich</surname><given-names>M.</given-names></name>
<name><surname>Block</surname><given-names>G.A.</given-names></name>
<etal/>
</person-group><article-title>Antibody Response to COVID-19 Vaccination in Patients Receiving Dialysis</article-title><source>J. Am. Soc. Nephrol.</source><year>2021</year><volume>32</volume><fpage>2435</fpage><lpage>2438</lpage><pub-id pub-id-type="doi">10.1681/ASN.2021050611</pub-id><pub-id pub-id-type="pmid">34117129</pub-id>
</element-citation></ref><ref id="B10-vaccines-12-01312"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Windpessl</surname><given-names>M.</given-names></name>
<name><surname>Bruchfeld</surname><given-names>A.</given-names></name>
<name><surname>Anders</surname><given-names>H.J.</given-names></name>
<name><surname>Kramer</surname><given-names>H.</given-names></name>
<name><surname>Waldman</surname><given-names>M.</given-names></name>
<name><surname>Renia</surname><given-names>L.</given-names></name>
<name><surname>Ng</surname><given-names>L.F.P.</given-names></name>
<name><surname>Xing</surname><given-names>Z.</given-names></name>
<name><surname>Kronbichler</surname><given-names>A.</given-names></name>
</person-group><article-title>COVID-19 vaccines and kidney disease</article-title><source>Nat. Reviews. Nephrol.</source><year>2021</year><volume>17</volume><fpage>291</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1038/s41581-021-00406-6</pub-id></element-citation></ref><ref id="B11-vaccines-12-01312"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bertrand</surname><given-names>D.</given-names></name>
<name><surname>Hamzaoui</surname><given-names>M.</given-names></name>
<name><surname>Lem&#x000e9;e</surname><given-names>V.</given-names></name>
<name><surname>Lamulle</surname><given-names>J.</given-names></name>
<name><surname>Hanoy</surname><given-names>M.</given-names></name>
<name><surname>Laurent</surname><given-names>C.</given-names></name>
<name><surname>Lebourg</surname><given-names>L.</given-names></name>
<name><surname>Etienne</surname><given-names>I.</given-names></name>
<name><surname>Lemoine</surname><given-names>M.</given-names></name>
<name><surname>Le Roy</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>Antibody and T Cell Response to SARS-CoV-2 Messenger RNA BNT162b2 Vaccine in Kidney Transplant Recipients and Hemodialysis Patients</article-title><source>J. Am. Soc. Nephrol.</source><year>2021</year><volume>32</volume><fpage>2147</fpage><lpage>2152</lpage><pub-id pub-id-type="doi">10.1681/ASN.2021040480</pub-id><pub-id pub-id-type="pmid">34112706</pub-id>
</element-citation></ref><ref id="B12-vaccines-12-01312"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Marion</surname><given-names>O.</given-names></name>
<name><surname>Abravanel</surname><given-names>F.</given-names></name>
<name><surname>Couat</surname><given-names>C.</given-names></name>
<name><surname>Faguer</surname><given-names>S.</given-names></name>
<name><surname>Esposito</surname><given-names>L.</given-names></name>
<name><surname>Hebral</surname><given-names>A.L.</given-names></name>
<name><surname>Izopet</surname><given-names>J.</given-names></name>
<name><surname>Kamar</surname><given-names>N.</given-names></name>
</person-group><article-title>Safety and Immunogenicity of Anti&#x02013;SARS-CoV-2 Messenger RNA Vaccines in Recipients of Solid Organ Transplants</article-title><source>Ann. Intern. Med.</source><year>2021</year><volume>174</volume><fpage>1336</fpage><lpage>1338</lpage><pub-id pub-id-type="doi">10.7326/M21-1341</pub-id><pub-id pub-id-type="pmid">34029487</pub-id>
</element-citation></ref><ref id="B13-vaccines-12-01312"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Simon</surname><given-names>B.</given-names></name>
<name><surname>Rubey</surname><given-names>H.</given-names></name>
<name><surname>Treipl</surname><given-names>A.</given-names></name>
<name><surname>Gromann</surname><given-names>M.</given-names></name>
<name><surname>Hemedi</surname><given-names>B.</given-names></name>
<name><surname>Zehetmayer</surname><given-names>S.</given-names></name>
<name><surname>Kirsch</surname><given-names>B.</given-names></name>
</person-group><article-title>Hemodialysis Patients Show a Highly Diminished Antibody Response after COVID-19 mRNA Vaccination Compared to Healthy Controls</article-title><source>Nephrol. Dial. Transplant.</source><year>2021</year><volume>36</volume><fpage>1709</fpage><lpage>1716</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfab179</pub-id><pub-id pub-id-type="pmid">33999200</pub-id>
</element-citation></ref><ref id="B14-vaccines-12-01312"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ziemba</surname><given-names>R.</given-names></name>
<name><surname>Campbell</surname><given-names>K.N.</given-names></name>
<name><surname>Yang</surname><given-names>T.H.</given-names></name>
<name><surname>Schaeffer</surname><given-names>S.E.</given-names></name>
<name><surname>Mayo</surname><given-names>K.M.</given-names></name>
<name><surname>McGann</surname><given-names>P.</given-names></name>
<name><surname>Quinn</surname><given-names>S.</given-names></name>
<name><surname>Roach</surname><given-names>J.</given-names></name>
<name><surname>Huff</surname><given-names>E.D.</given-names></name>
</person-group><article-title>Excess Death Estimates in Patients with End-Stage Renal Disease&#x02014;United States, February-August 2020</article-title><source>MMWR Morb. Mortal. Wkly. Rep.</source><year>2021</year><volume>70</volume><fpage>825</fpage><lpage>829</lpage><pub-id pub-id-type="doi">10.15585/mmwr.mm7022e2</pub-id><pub-id pub-id-type="pmid">34081687</pub-id>
</element-citation></ref><ref id="B15-vaccines-12-01312"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Banham</surname><given-names>G.D.</given-names></name>
<name><surname>Godlee</surname><given-names>A.</given-names></name>
<name><surname>Faustini</surname><given-names>S.E.</given-names></name>
<name><surname>Cunningham</surname><given-names>A.F.</given-names></name>
<name><surname>Richter</surname><given-names>A.</given-names></name>
<name><surname>Harper</surname><given-names>L.</given-names></name>
<name><surname>Group</surname><given-names>o.b.o.t.C.H.B.S.</given-names></name>
</person-group><article-title>Hemodialysis Patients Make Long-Lived Antibodies against SARS-CoV-2 that May Be Associated with Reduced Reinfection</article-title><source>J. Am. Soc. Nephrol.</source><year>2021</year><volume>32</volume><fpage>2140</fpage><lpage>2142</lpage><pub-id pub-id-type="doi">10.1681/ASN.2021020188</pub-id><pub-id pub-id-type="pmid">34341181</pub-id>
</element-citation></ref><ref id="B16-vaccines-12-01312"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Boyarsky</surname><given-names>B.J.</given-names></name>
<name><surname>Werbel</surname><given-names>W.A.</given-names></name>
<name><surname>Avery</surname><given-names>R.K.</given-names></name>
<name><surname>Tobian</surname><given-names>A.A.R.</given-names></name>
<name><surname>Massie</surname><given-names>A.B.</given-names></name>
<name><surname>Segev</surname><given-names>D.L.</given-names></name>
<name><surname>Garonzik-Wang</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients</article-title><source>JAMA</source><year>2021</year><volume>325</volume><fpage>2204</fpage><lpage>2206</lpage><pub-id pub-id-type="doi">10.1001/jama.2021.7489</pub-id><pub-id pub-id-type="pmid">33950155</pub-id>
</element-citation></ref><ref id="B17-vaccines-12-01312"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Boyarsky</surname><given-names>B.J.</given-names></name>
<name><surname>Werbel</surname><given-names>W.A.</given-names></name>
<name><surname>Avery</surname><given-names>R.K.</given-names></name>
<name><surname>Tobian</surname><given-names>A.A.R.</given-names></name>
<name><surname>Massie</surname><given-names>A.B.</given-names></name>
<name><surname>Segev</surname><given-names>D.L.</given-names></name>
<name><surname>Garonzik-Wang</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients</article-title><source>JAMA</source><year>2021</year><volume>325</volume><fpage>1784</fpage><lpage>1786</lpage><pub-id pub-id-type="doi">10.1001/jama.2021.4385</pub-id><pub-id pub-id-type="pmid">33720292</pub-id>
</element-citation></ref><ref id="B18-vaccines-12-01312"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Benotmane</surname><given-names>I.</given-names></name>
<name><surname>Gautier</surname><given-names>G.</given-names></name>
<name><surname>Perrin</surname><given-names>P.</given-names></name>
<name><surname>Olagne</surname><given-names>J.</given-names></name>
<name><surname>Cognard</surname><given-names>N.</given-names></name>
<name><surname>Fafi-Kremer</surname><given-names>S.</given-names></name>
<name><surname>Caillard</surname><given-names>S.</given-names></name>
</person-group><article-title>Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients with Minimal Serologic Response to 2 Doses</article-title><source>JAMA</source><year>2021</year><volume>326</volume><fpage>1063</fpage><lpage>1065</lpage><pub-id pub-id-type="doi">10.1001/jama.2021.12339</pub-id><pub-id pub-id-type="pmid">34297036</pub-id>
</element-citation></ref><ref id="B19-vaccines-12-01312"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ducloux</surname><given-names>D.</given-names></name>
<name><surname>Colladant</surname><given-names>M.</given-names></name>
<name><surname>Chabannes</surname><given-names>M.</given-names></name>
<name><surname>Yannaraki</surname><given-names>M.</given-names></name>
<name><surname>Courivaud</surname><given-names>C.</given-names></name>
</person-group><article-title>Humoral response after three doses of BNT162b2 mRNA COVID-19 vaccine in patients on hemodialysis</article-title><source>Kidney Int.</source><year>2021</year><volume>100</volume><fpage>702</fpage><lpage>704</lpage><pub-id pub-id-type="doi">10.1016/j.kint.2021.06.025</pub-id></element-citation></ref><ref id="B20-vaccines-12-01312"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kamar</surname><given-names>N.</given-names></name>
<name><surname>Abravanel</surname><given-names>F.</given-names></name>
<name><surname>Marion</surname><given-names>O.</given-names></name>
<name><surname>Couat</surname><given-names>C.</given-names></name>
<name><surname>Izopet</surname><given-names>J.</given-names></name>
<name><surname>Del Bello</surname><given-names>A.</given-names></name>
</person-group><article-title>Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients</article-title><source>N. Engl. J. Med.</source><year>2021</year><volume>385</volume><fpage>661</fpage><lpage>662</lpage><pub-id pub-id-type="doi">10.1056/NEJMc2108861</pub-id><pub-id pub-id-type="pmid">34161700</pub-id>
</element-citation></ref><ref id="B21-vaccines-12-01312"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Han</surname><given-names>A.</given-names></name>
<name><surname>Min</surname><given-names>S.</given-names></name>
<name><surname>Jo</surname><given-names>E.A.</given-names></name>
<name><surname>Lee</surname><given-names>H.</given-names></name>
<name><surname>Kim</surname><given-names>Y.C.</given-names></name>
<name><surname>Han</surname><given-names>S.S.</given-names></name>
<name><surname>Kang</surname><given-names>H.G.</given-names></name>
<name><surname>Ahn</surname><given-names>Y.H.</given-names></name>
<name><surname>Oh</surname><given-names>I.</given-names></name>
<name><surname>Song</surname><given-names>E.Y.</given-names></name>
<etal/>
</person-group><article-title>Association between Low Anti-spike Antibody Levels After the Third Dose of SARS-CoV-2 Vaccination and Hospitalization due to Symptomatic Breakthrough Infection in Kidney Transplant Recipients</article-title><source>Ann. Lab. Med.</source><year>2023</year><volume>44</volume><fpage>64</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.3343/alm.2024.44.1.64</pub-id><pub-id pub-id-type="pmid">37665287</pub-id>
</element-citation></ref><ref id="B22-vaccines-12-01312"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Weiss</surname><given-names>A.</given-names></name>
<name><surname>Hendrickx</surname><given-names>R.</given-names></name>
<name><surname>Stensgaard</surname><given-names>E.</given-names></name>
<name><surname>Jellings&#x000f8;</surname><given-names>M.</given-names></name>
<name><surname>Sommer</surname><given-names>M.O.</given-names></name>
</person-group><article-title>Kidney Transplant and Dialysis Patients Remain at Increased Risk for Succumbing to COVID-19</article-title><source>Transplantation</source><year>2023</year><volume>107</volume><fpage>1136</fpage><lpage>1138</lpage><pub-id pub-id-type="doi">10.1097/TP.0000000000004462</pub-id><pub-id pub-id-type="pmid">36584380</pub-id>
</element-citation></ref><ref id="B23-vaccines-12-01312"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barreiro</surname><given-names>P.</given-names></name>
<name><surname>Candel</surname><given-names>F.J.</given-names></name>
<name><surname>Carretero</surname><given-names>M.M.</given-names></name>
<name><surname>San Rom&#x000e1;n</surname><given-names>J.</given-names></name>
</person-group><article-title>Risk of severe COVID in solid organ transplant recipient</article-title><source>Rev. Esp. Quimioter.</source><year>2023</year><volume>36</volume><issue>(Suppl. S1)</issue><fpage>15</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.37201/req/s01.04.2023</pub-id><pub-id pub-id-type="pmid">37997864</pub-id>
</element-citation></ref><ref id="B24-vaccines-12-01312"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chiang</surname><given-names>T.P.Y.</given-names></name>
<name><surname>Abedon</surname><given-names>A.T.</given-names></name>
<name><surname>Alejo</surname><given-names>J.L.</given-names></name>
<name><surname>Segev</surname><given-names>D.L.</given-names></name>
<name><surname>Massie</surname><given-names>A.B.</given-names></name>
<name><surname>Werbel</surname><given-names>W.A.</given-names></name>
</person-group><article-title>Incident COVID-19 and Hospitalizations by Variant Era Among Vaccinated Solid Organ Transplant Recipients</article-title><source>JAMA Netw. Open</source><year>2023</year><volume>6</volume><fpage>e2329736</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2023.29736</pub-id><pub-id pub-id-type="pmid">37594763</pub-id>
</element-citation></ref><ref id="B25-vaccines-12-01312"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pinchera</surname><given-names>B.</given-names></name>
<name><surname>Buonomo</surname><given-names>A.R.</given-names></name>
<name><surname>Trucillo</surname><given-names>E.</given-names></name>
<name><surname>Susini</surname><given-names>S.</given-names></name>
<name><surname>D&#x02019;Agostino</surname><given-names>A.</given-names></name>
<name><surname>Di Filippo</surname><given-names>I.</given-names></name>
<name><surname>Tanzillo</surname><given-names>A.</given-names></name>
<name><surname>Villari</surname><given-names>R.</given-names></name>
<name><surname>Carrano</surname><given-names>R.</given-names></name>
<name><surname>Troisi</surname><given-names>R.I.</given-names></name>
<etal/>
</person-group><article-title>COVID-19 in solid organ transplant recipients after 2 years of pandemic: Outcome and impact of antiviral treatments in a single-center study</article-title><source>Front. Transplant.</source><year>2023</year><volume>2</volume><elocation-id>1095225</elocation-id><pub-id pub-id-type="doi">10.3389/frtra.2023.1095225</pub-id><pub-id pub-id-type="pmid">38993895</pub-id>
</element-citation></ref><ref id="B26-vaccines-12-01312"><label>26.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<name><surname>Fernandez</surname><given-names>C.</given-names></name>
</person-group><article-title>En Rep&#x000fa;blica Dominicana, 5275 Pacientes Reciben Hemodi&#x000e1;lisis y 500 Esperan un Ri&#x000f1;&#x000f3;n</article-title><source>Diario Libre</source><month>March</month><year>2023</year><comment>Available online: <ext-link xlink:href="https://www.diariolibre.com/actualidad/salud/2023/03/10/en-rd-5275-reciben-hemodialisis-y-500-esperan-un-rinon/2250175" ext-link-type="uri">https://www.diariolibre.com/actualidad/salud/2023/03/10/en-rd-5275-reciben-hemodialisis-y-500-esperan-un-rinon/2250175</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-03">(accessed on 3 September 2024)</date-in-citation></element-citation></ref><ref id="B27-vaccines-12-01312"><label>27.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>Instituto Nacional de Coordinaci&#x000f3;n de Trasplante (INCORT)</collab>
</person-group><article-title>Trasplantes de &#x000f3;rganos y Tejidos de la Rep&#x000fa;blica Dominicana 2008&#x02013;2023</article-title><source>Incort. Santo Domingo, Dominican Republic</source><year>2024</year><comment>Available online: <ext-link xlink:href="https://incortrd.com/trasplantes-de-organos-y-tejidos-de-la-republica-dominicana-2008-2022/" ext-link-type="uri">https://incortrd.com/trasplantes-de-organos-y-tejidos-de-la-republica-dominicana-2008-2022/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-08-19">(accessed on 19 August 2024)</date-in-citation></element-citation></ref><ref id="B28-vaccines-12-01312"><label>28.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>Ministerio de Salud P&#x000fa;blica de La Rep&#x000fa;blica Dominicana</collab>
</person-group><article-title>Gobierno Presenta Plan Nacional de Vacunaci&#x000f3;n Contra COVID-19</article-title><day>15</day><month>February</month><year>2021</year><comment>Available online: <ext-link xlink:href="https://dominicantoday.com/dr/health/2021/02/13/vaccines-that-the-country-will-use-are-very-effective/" ext-link-type="uri">https://dominicantoday.com/dr/health/2021/02/13/vaccines-that-the-country-will-use-are-very-effective/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-08-02">(accessed on 2 August 2024)</date-in-citation></element-citation></ref><ref id="B29-vaccines-12-01312"><label>29.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>Dominican Today</collab>
</person-group><article-title>Vaccines That the Dominican Republic Will Use Are Very Effective</article-title><day>13</day><month>February</month><year>2021</year><comment>Available online: <ext-link xlink:href="https://dominicantoday.com/dr/health/2021/02/13/vaccines-that-the-country-will-use-are-very-effective/" ext-link-type="uri">https://dominicantoday.com/dr/health/2021/02/13/vaccines-that-the-country-will-use-are-very-effective/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-08-02">(accessed on 2 August 2024)</date-in-citation></element-citation></ref><ref id="B30-vaccines-12-01312"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pecora</surname><given-names>N.D.</given-names></name>
<name><surname>Zand</surname><given-names>M.S.</given-names></name>
</person-group><article-title>Measuring the Serologic Response to Severe Acute Respiratory Syndrome Coronavirus 2: Methods and Meaning</article-title><source>Clin. Lab. Med.</source><year>2020</year><volume>40</volume><fpage>603</fpage><lpage>614</lpage><pub-id pub-id-type="doi">10.1016/j.cll.2020.08.014</pub-id><pub-id pub-id-type="pmid">33121625</pub-id>
</element-citation></ref><ref id="B31-vaccines-12-01312"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>D.</given-names></name>
<name><surname>Zhou</surname><given-names>Q.</given-names></name>
<name><surname>Wiltse</surname><given-names>A.</given-names></name>
<name><surname>Zand</surname><given-names>M.S.</given-names></name>
</person-group><article-title>Antibody Mediated Immunity to SARS-CoV-2 and Human Coronaviruses: Multiplex Beads Assay and Volumetric Absorptive Microsampling to Generate Immune Repertoire Cartography</article-title><source>Front. Immunol.</source><year>2021</year><volume>12</volume><elocation-id>696370</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2021.696370</pub-id><pub-id pub-id-type="pmid">34386006</pub-id>
</element-citation></ref><ref id="B32-vaccines-12-01312"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kompaniyets</surname><given-names>L.</given-names></name>
<name><surname>Pennington</surname><given-names>A.F.</given-names></name>
<name><surname>Goodman</surname><given-names>A.B.</given-names></name>
<name><surname>Rosenblum</surname><given-names>H.G.</given-names></name>
<name><surname>Belay</surname><given-names>B.</given-names></name>
<name><surname>Ko</surname><given-names>J.Y.</given-names></name>
<name><surname>Chevinsky</surname><given-names>J.R.</given-names></name>
<name><surname>Schieber</surname><given-names>L.Z.</given-names></name>
<name><surname>Summers</surname><given-names>A.D.</given-names></name>
<name><surname>Lavery</surname><given-names>A.M.</given-names></name>
<etal/>
</person-group><article-title>Underlying Medical Conditions and Severe Illness Among 540,667 Adults Hospitalized with COVID-19, March 2020&#x02013;March 2021</article-title><source>Prev. Chronic. Dis.</source><year>2021</year><volume>18</volume><fpage>E66</fpage><pub-id pub-id-type="doi">10.5888/pcd18.210123</pub-id><pub-id pub-id-type="pmid">34197283</pub-id>
</element-citation></ref><ref id="B33-vaccines-12-01312"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>D.</given-names></name>
<name><surname>Wiltse</surname><given-names>A.</given-names></name>
<name><surname>Emo</surname><given-names>J.</given-names></name>
<name><surname>Hilchey</surname><given-names>S.P.</given-names></name>
<name><surname>Zand</surname><given-names>M.S.</given-names></name>
</person-group><article-title>Application of volumetric absorptive microsampling (VAMS) to measure multidimensional anti-influenza IgG antibodies by the mPlex-Flu assay</article-title><source>J. Clin. Transl. Sci.</source><year>2019</year><volume>3</volume><fpage>332</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1017/cts.2019.410</pub-id><pub-id pub-id-type="pmid">31827907</pub-id>
</element-citation></ref><ref id="B34-vaccines-12-01312"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bursac</surname><given-names>Z.</given-names></name>
<name><surname>Gauss</surname><given-names>C.H.</given-names></name>
<name><surname>Williams</surname><given-names>D.K.</given-names></name>
<name><surname>Hosmer</surname><given-names>D.W.</given-names></name>
</person-group><article-title>Purposeful selection of variables in logistic regression</article-title><source>Source Code Biol. Med.</source><year>2008</year><volume>3</volume><elocation-id>17</elocation-id><pub-id pub-id-type="doi">10.1186/1751-0473-3-17</pub-id><pub-id pub-id-type="pmid">19087314</pub-id>
</element-citation></ref><ref id="B35-vaccines-12-01312"><label>35.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>United Nations Population Fund (UNFPA)</collab>
</person-group><article-title>Encuesta Nacional de Autopercepci&#x000f3;n Racial y &#x000c9;tnica en Rep&#x000fa;blica Dominicana</article-title><month>March</month><year>2022</year><comment>Available online: <ext-link xlink:href="https://dominicanrepublic.unfpa.org/es/publications/breve-encuesta-nacional-de-autopercepcion-racial-y-etnica-en-republica-dominicana" ext-link-type="uri">https://dominicanrepublic.unfpa.org/es/publications/breve-encuesta-nacional-de-autopercepcion-racial-y-etnica-en-republica-dominicana</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-03">(accessed on 3 September 2024)</date-in-citation></element-citation></ref><ref id="B36-vaccines-12-01312"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Narongkiatikhun</surname><given-names>P.</given-names></name>
<name><surname>Noppakun</surname><given-names>K.</given-names></name>
<name><surname>Chaiwarith</surname><given-names>R.</given-names></name>
<name><surname>Winichakoon</surname><given-names>P.</given-names></name>
<name><surname>Vongsanim</surname><given-names>S.</given-names></name>
<name><surname>Suteeka</surname><given-names>Y.</given-names></name>
<name><surname>Pongsuwan</surname><given-names>K.</given-names></name>
<name><surname>Kusirisin</surname><given-names>P.</given-names></name>
<name><surname>Wongsarikan</surname><given-names>N.</given-names></name>
<name><surname>Fanhchaksai</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>Immunogenicity and Safety of Homologous and Heterologous Prime-Boost of CoronaVac<sup>&#x000ae;</sup> and ChAdOx1 nCoV-19 among Hemodialysis Patients: An Observational Prospective Cohort Study</article-title><source>Vaccines</source><year>2023</year><volume>11</volume><elocation-id>715</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines11040715</pub-id><pub-id pub-id-type="pmid">37112627</pub-id>
</element-citation></ref><ref id="B37-vaccines-12-01312"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>P&#x000e9;rez-Then</surname><given-names>E.</given-names></name>
<name><surname>Lucas</surname><given-names>C.</given-names></name>
<name><surname>Monteiro</surname><given-names>V.S.</given-names></name>
<name><surname>Miric</surname><given-names>M.</given-names></name>
<name><surname>Brache</surname><given-names>V.</given-names></name>
<name><surname>Cochon</surname><given-names>L.</given-names></name>
<name><surname>Vogels</surname><given-names>C.B.F.</given-names></name>
<name><surname>Malik</surname><given-names>A.A.</given-names></name>
<name><surname>De la Cruz</surname><given-names>E.</given-names></name>
<name><surname>Jorge</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination</article-title><source>Nat. Med.</source><year>2022</year><volume>28</volume><fpage>481</fpage><lpage>485</lpage><pub-id pub-id-type="doi">10.1038/s41591-022-01705-6</pub-id><pub-id pub-id-type="pmid">35051990</pub-id>
</element-citation></ref><ref id="B38-vaccines-12-01312"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ramos</surname><given-names>A.</given-names></name>
<name><surname>Cardoso</surname><given-names>M.J.</given-names></name>
<name><surname>Ribeiro</surname><given-names>L.</given-names></name>
<name><surname>Guimar&#x000e3;es</surname><given-names>J.T.</given-names></name>
</person-group><article-title>Assessing SARS-CoV-2 Neutralizing Antibodies after BNT162b2 Vaccination and Their Correlation with SARS-CoV-2 IgG Anti-S1, Anti-RBD and Anti-S2 Serological Titers</article-title><source>Diagnostics</source><year>2022</year><volume>12</volume><elocation-id>205</elocation-id><pub-id pub-id-type="doi">10.3390/diagnostics12010205</pub-id><pub-id pub-id-type="pmid">35054372</pub-id>
</element-citation></ref><ref id="B39-vaccines-12-01312"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Anichini</surname><given-names>G.</given-names></name>
<name><surname>Terrosi</surname><given-names>C.</given-names></name>
<name><surname>Gandolfo</surname><given-names>C.</given-names></name>
<name><surname>Gori Savellini</surname><given-names>G.</given-names></name>
<name><surname>Fabrizi</surname><given-names>S.</given-names></name>
<name><surname>Miceli</surname><given-names>G.B.</given-names></name>
<name><surname>Cusi</surname><given-names>M.G.</given-names></name>
</person-group><article-title>SARS-CoV-2 Antibody Response in Persons with Past Natural Infection</article-title><source>N. Engl. J. Med.</source><year>2021</year><volume>385</volume><fpage>90</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1056/NEJMc2103825</pub-id><pub-id pub-id-type="pmid">33852796</pub-id>
</element-citation></ref><ref id="B40-vaccines-12-01312"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>K.</given-names></name>
<name><surname>Dai</surname><given-names>L.</given-names></name>
<name><surname>Gao</surname><given-names>G.F.</given-names></name>
</person-group><article-title>Humoral and cellular immunity and the safety of COVID-19 vaccines: A summary of data published by 21 May 2021</article-title><source>Int. Immunol.</source><year>2021</year><volume>33</volume><fpage>529</fpage><lpage>540</lpage><pub-id pub-id-type="doi">10.1093/intimm/dxab061</pub-id><pub-id pub-id-type="pmid">34491327</pub-id>
</element-citation></ref><ref id="B41-vaccines-12-01312"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stumpf</surname><given-names>J.</given-names></name>
<name><surname>Siepmann</surname><given-names>T.</given-names></name>
<name><surname>Lindner</surname><given-names>T.</given-names></name>
<name><surname>Karger</surname><given-names>C.</given-names></name>
<name><surname>Schw&#x000f6;bel</surname><given-names>J.</given-names></name>
<name><surname>Anders</surname><given-names>L.</given-names></name>
<name><surname>Faulhaber-Walter</surname><given-names>R.</given-names></name>
<name><surname>Schewe</surname><given-names>J.</given-names></name>
<name><surname>Martin</surname><given-names>H.</given-names></name>
<name><surname>Schirutschke</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine</article-title><source>Lancet Reg. Health Eur.</source><year>2021</year><volume>9</volume><fpage>100178</fpage><pub-id pub-id-type="doi">10.1016/j.lanepe.2021.100178</pub-id><pub-id pub-id-type="pmid">34318288</pub-id>
</element-citation></ref><ref id="B42-vaccines-12-01312"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rouphael</surname><given-names>N.</given-names></name>
<name><surname>Bausch-Jurken</surname><given-names>M.</given-names></name>
</person-group><article-title>COVID-19 Vaccination Among Patients Receiving Maintenance Renal Replacement Therapy: Immune Response, Real-World Effectiveness, and Implications for the Future</article-title><source>J. Infect. Dis.</source><year>2023</year><volume>228</volume><fpage>S46</fpage><lpage>S54</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiad162</pub-id><pub-id pub-id-type="pmid">37539761</pub-id>
</element-citation></ref><ref id="B43-vaccines-12-01312"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jarlhelt</surname><given-names>I.</given-names></name>
<name><surname>P&#x000e9;rez-Al&#x000f3;s</surname><given-names>L.</given-names></name>
<name><surname>Bayarri-Olmos</surname><given-names>R.</given-names></name>
<name><surname>Hansen</surname><given-names>C.B.</given-names></name>
<name><surname>Petersen</surname><given-names>M.S.</given-names></name>
<name><surname>Weihe</surname><given-names>P.</given-names></name>
<name><surname>Armenteros</surname><given-names>J.J.A.</given-names></name>
<name><surname>Madsen</surname><given-names>J.R.</given-names></name>
<name><surname>Nielsen</surname><given-names>J.P.S.</given-names></name>
<name><surname>Hilsted</surname><given-names>L.M.</given-names></name>
<etal/>
</person-group><article-title>Distinguishing SARS-CoV-2 infection and vaccine responses up to 18 months post-infection using nucleocapsid protein and receptor-binding domain antibodies</article-title><source>Microbiol. Spectr.</source><year>2023</year><volume>11</volume><fpage>e01796-23</fpage><pub-id pub-id-type="doi">10.1128/spectrum.01796-23</pub-id><pub-id pub-id-type="pmid">37738355</pub-id>
</element-citation></ref><ref id="B44-vaccines-12-01312"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aguilar-Bretones</surname><given-names>M.</given-names></name>
<name><surname>Fouchier</surname><given-names>R.A.M.</given-names></name>
<name><surname>Koopmans</surname><given-names>M.P.G.</given-names></name>
<name><surname>van Nierop</surname><given-names>G.P.</given-names></name>
</person-group><article-title>Impact of antigenic evolution and original antigenic sin on SARS-CoV-2 immunity</article-title><source>J. Clin. Investig.</source><year>2023</year><volume>133</volume><fpage>e162192</fpage><pub-id pub-id-type="doi">10.1172/JCI162192</pub-id><pub-id pub-id-type="pmid">36594464</pub-id>
</element-citation></ref><ref id="B45-vaccines-12-01312"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Qaqish</surname><given-names>A.</given-names></name>
<name><surname>Abbas</surname><given-names>M.M.</given-names></name>
<name><surname>Al-Tamimi</surname><given-names>M.</given-names></name>
<name><surname>Abbas</surname><given-names>M.A.</given-names></name>
<name><surname>Al-Omari</surname><given-names>M.</given-names></name>
<name><surname>Alqassieh</surname><given-names>R.</given-names></name>
</person-group><article-title>SARS-CoV-2 Antinucleocapsid Antibody Response of mRNA and Inactivated Virus Vaccines Compared to Unvaccinated Individuals</article-title><source>Vaccines</source><year>2022</year><volume>10</volume><elocation-id>643</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines10050643</pub-id><pub-id pub-id-type="pmid">35632399</pub-id>
</element-citation></ref><ref id="B46-vaccines-12-01312"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Eren Sadio&#x0011f;lu</surname><given-names>R.</given-names></name>
<name><surname>Demir</surname><given-names>E.</given-names></name>
<name><surname>Evren</surname><given-names>E.</given-names></name>
<name><surname>Aktar</surname><given-names>M.</given-names></name>
<name><surname>&#x0015e;afak</surname><given-names>S.</given-names></name>
<name><surname>Artan</surname><given-names>A.S.</given-names></name>
<name><surname>Me&#x0015f;e</surname><given-names>S.</given-names></name>
<name><surname>A&#x0011f;a&#x000e7;fidan</surname><given-names>A.</given-names></name>
<name><surname>&#x000c7;&#x00131;nar</surname><given-names>G.</given-names></name>
<name><surname>&#x000d6;nel</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Antibody response to two doses of inactivated SARS-CoV-2 vaccine (CoronaVac) in kidney transplant recipients</article-title><source>Transpl. Infect. Dis.</source><year>2021</year><volume>23</volume><fpage>e13740</fpage><pub-id pub-id-type="doi">10.1111/tid.13740</pub-id><pub-id pub-id-type="pmid">34606134</pub-id>
</element-citation></ref><ref id="B47-vaccines-12-01312"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ibrahim</surname><given-names>K.Y.</given-names></name>
<name><surname>Moreira</surname><given-names>R.M.</given-names></name>
<name><surname>Santos</surname><given-names>C.F.D.</given-names></name>
<name><surname>Strabelli</surname><given-names>T.M.V.</given-names></name>
<name><surname>Beliz&#x000e1;rio</surname><given-names>J.C.</given-names></name>
<name><surname>Pinto</surname><given-names>M.I.M.</given-names></name>
<name><surname>Marinho</surname><given-names>A.</given-names></name>
<name><surname>Pereira</surname><given-names>J.M.</given-names></name>
<name><surname>Mello</surname><given-names>L.S.</given-names></name>
<name><surname>Ando</surname><given-names>M.C.</given-names></name>
<etal/>
</person-group><article-title>Immunogenicity of COVID-19 adsorbed inactivated vaccine (CoronaVac) and additional doses of mRNA BNT162b2 vaccine in immunocompromised adults compared with immunocompetent persons</article-title><source>Rev. Inst. Med. Trop. S&#x000e3;o Paulo</source><year>2024</year><volume>66</volume><fpage>e24</fpage><pub-id pub-id-type="doi">10.1590/S1678-9946202466024</pub-id><pub-id pub-id-type="pmid">38656040</pub-id>
</element-citation></ref><ref id="B48-vaccines-12-01312"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lin</surname><given-names>C.</given-names></name>
<name><surname>Tu</surname><given-names>P.</given-names></name>
<name><surname>Beitsch</surname><given-names>L.M.</given-names></name>
</person-group><article-title>Confidence and Receptivity for COVID-19 Vaccines: A Rapid Systematic Review</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>16</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9010016</pub-id><pub-id pub-id-type="pmid">33396832</pub-id>
</element-citation></ref><ref id="B49-vaccines-12-01312"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wallace</surname><given-names>H.</given-names></name>
<name><surname>Mount</surname><given-names>P.F.</given-names></name>
</person-group><article-title>COVID-19 beliefs and vaccination uptake in dialysis patients: Lessons from an anonymous patient survey</article-title><source>Intern. Med. J.</source><year>2022</year><volume>52</volume><fpage>1488</fpage><lpage>1494</lpage><pub-id pub-id-type="doi">10.1111/imj.15636</pub-id><pub-id pub-id-type="pmid">34841628</pub-id>
</element-citation></ref><ref id="B50-vaccines-12-01312"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fisher</surname><given-names>K.A.</given-names></name>
<name><surname>Bloomstone</surname><given-names>S.J.</given-names></name>
<name><surname>Walder</surname><given-names>J.</given-names></name>
<name><surname>Crawford</surname><given-names>S.</given-names></name>
<name><surname>Fouayzi</surname><given-names>H.</given-names></name>
<name><surname>Mazor</surname><given-names>K.M.</given-names></name>
</person-group><article-title>Attitudes Toward a Potential SARS-CoV-2 Vaccine: A Survey of U.S. Adults</article-title><source>Ann. Intern. Med.</source><year>2020</year><volume>173</volume><fpage>964</fpage><lpage>973</lpage><pub-id pub-id-type="doi">10.7326/M20-3569</pub-id><pub-id pub-id-type="pmid">32886525</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="vaccines-12-01312-f001"><label>Figure 1</label><caption><p>Data flow diagram showing study cohorts and design. We studied 271 capillary blood samples from 70 subjects at 5 time points after vaccination. Three cohorts were considered: control (<italic toggle="yes">n</italic> = 33), hemodialysis (<italic toggle="yes">n</italic> = 13), and transplant (<italic toggle="yes">n</italic> = 24), stratified by prior history of COVID-19 infection. Day 0 corresponds to the samples that were collected immediately prior to the first vaccine, and day 21/28 indicates the samples collected prior to the second dose, depending on the vaccine schedule. Additional samples had been collected on days 42, 70 (2 and 4 weeks after the second vaccine dose), and before any booster applications, if administered, as well as 6 months after the last received dose.</p></caption><graphic xlink:href="vaccines-12-01312-g001" position="float"/></fig><fig position="float" id="vaccines-12-01312-f002"><label>Figure 2</label><caption><p>Total full-length anti-spike (green solid line), S-RBD (green dashed line), and S2 (orange solid line) subunit IgG concentrations were measured in control (<italic toggle="yes">n</italic> = 33), hemodialysis (<italic toggle="yes">n</italic> = 13), and transplant recipient (<italic toggle="yes">n</italic> = 24) cohorts. Day 0 corresponds to the day of the first vaccine dose. Data were fitted to a spline curve for each group, with 95% confidence levels noted as gray bands. Significant differences in antibody concentrations between time points, defined as <inline-formula><mml:math id="mm8" overflow="scroll"><mml:mrow><mml:mrow><mml:mn>0.2</mml:mn><mml:msub><mml:mo form="prefix">log</mml:mo><mml:mn>10</mml:mn></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> ng/mL, were detected based on the GLMM analysis and determined by <italic toggle="yes">p</italic>-values &#x0003c; 0.05). Statistically significant correlations were found between the different subunits of the spike protein, with group-specific R values.</p></caption><graphic xlink:href="vaccines-12-01312-g002" position="float"/></fig><fig position="float" id="vaccines-12-01312-f003"><label>Figure 3</label><caption><p>SARS-CoV-2 IgG anti-S and anti-N IgG distribution estimated by days after first vaccine dose. Total anti-S (green solid line), anti S-RBD (green dashed line), and anti-N (orange solid line) IgG concentrations for control (<italic toggle="yes">n</italic> = 104), hemodialysis (<italic toggle="yes">n</italic> = 47), and transplant (<italic toggle="yes">n</italic> = 120) cohorts were measured using a multiplex assay. Day 0 corresponds to the day of the first vaccine dose. The data were fitted to a spline curve for each group, with 95% confidence levels noted by the gray bands. Arrows indicate the mean time for the second (36.6 &#x000b1; 34.1 days) and booster vaccinations (154.3 &#x000b1; 41.1 days). The correlation between anti-S and anti-N over time is R = 0.54, with group-specific R values displayed in the figure. A statistically significant difference in anti-S levels was observed between the HD and CO groups (<italic toggle="yes">p</italic> &#x0003c; 0.001), with the most notable difference occurring on day 130 after the first vaccine dose (<italic toggle="yes">p</italic> = 0.014). In CO, the anti-N levels increased after 150 days, while, unexpectedly, anti-S IgG declined compared to the levels observed on day 50 (<italic toggle="yes">p</italic> &#x0003c; 0.001). This pattern suggests a potential increase in infections during the first 130 days after the first vaccine. Conversely, the TR group exhibited a statistically significant (<italic toggle="yes">p</italic> &#x0003c; 0.05) delayed yet continuous increase in anti-S levels, beginning around day 65. This trend suggests a prolonged immune response and potentially greater variability in this group. Follow-up for the control group was limited to 300 days, with some subject dropout (see <xref rid="vaccines-12-01312-t003" ref-type="table">Table 3</xref>).</p></caption><graphic xlink:href="vaccines-12-01312-g003" position="float"/></fig><fig position="float" id="vaccines-12-01312-f004"><label>Figure 4</label><caption><p>Distribution of SARS-CoV-2 IgG antibodies against spike and nucleocapsid proteins by cohort and COVID-19 status before vaccination. Concentrations of total anti-S (green lines on the left) and anti-N (orange lines on the right) IgG measured in the three studied groups after first vaccine dose. Solid lines represent subjects with a reported prior natural infection (<italic toggle="yes">n</italic> = 31), while dashed lines represent those without a history of COVID-19 infection (<italic toggle="yes">n</italic> = 39). Day 0 corresponds to the day of their first vaccine dose. Aggregate data points were fitted to a spline curve for each group, with 95% confidence levels noted by the gray bands. Arrows indicate mean times for second (36.6 &#x000b1; 34.1 days) and booster vaccinations (154.3 &#x000b1; 41.1 days).</p></caption><graphic xlink:href="vaccines-12-01312-g004" position="float"/></fig><fig position="float" id="vaccines-12-01312-f005"><label>Figure 5</label><caption><p>SARS-CoV-2 IgG anti-spike and anti-nucleocapsid protein distribution by cohort and vaccine type. Total anti-S and anti-N IgG concentrations were measured in control (<italic toggle="yes">n</italic> = 33), hemodialysis (<italic toggle="yes">n</italic> = 13), and transplant (<italic toggle="yes">n</italic> = 24) cohorts via multiplex assay. Day 0 refers to the day when the participants received their first vaccine dose. Arrows indicate mean times for second (36.6 &#x000b1; 34.1 days) and booster vaccinations (154.3 &#x000b1; 41.1 days). Among the subjects, 43 individuals (63.24%) were vaccinated with BNT162b2, while 25 individuals (36.76%) received CoronaVac. Additionally, 8 participants received homologous boosters, and 7 received heterologous boosters.</p></caption><graphic xlink:href="vaccines-12-01312-g005" position="float"/></fig><table-wrap position="float" id="vaccines-12-01312-t001"><object-id pub-id-type="pii">vaccines-12-01312-t001_Table 1</object-id><label>Table 1</label><caption><p>The participant pool comprised a total of 70 individuals, distributed across three cohorts: control (<italic toggle="yes">n</italic> = 33), hemodialysis (<italic toggle="yes">n</italic> = 13), and transplant (<italic toggle="yes">n</italic> = 24). The groups were stratified based on the subjects&#x02019; prior history of COVID-19: positive (<italic toggle="yes">n</italic> = 31) or negative (<italic toggle="yes">n</italic> = 39). Statistical comparisons for categorical variables were performed using Pearson&#x02019;s Chi-squared test and Fisher&#x02019;s exact test. Categorical variables are presented as counts (percentages).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-bottom:solid thin;border-top:solid thin" rowspan="1" colspan="1">Characteristic</th><th align="right" valign="middle" style="border-bottom:solid thin;border-top:solid thin" rowspan="1" colspan="1">Control, <italic toggle="yes">n</italic> = 33&#x000a0;<sup>1</sup></th><th align="right" valign="middle" style="border-bottom:solid thin;border-top:solid thin" rowspan="1" colspan="1">Hemodialysis, <italic toggle="yes">n</italic> = 13&#x000a0;<sup>1</sup></th><th align="right" valign="middle" style="border-bottom:solid thin;border-top:solid thin" rowspan="1" colspan="1">Transplant, <italic toggle="yes">n</italic> = 24&#x000a0;<sup>1</sup></th><th align="right" valign="middle" style="border-bottom:solid thin;border-top:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value&#x000a0;<sup>2</sup></th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Age</bold>
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.150</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0; 18&#x02013;24</td><td align="right" valign="middle" rowspan="1" colspan="1">6 (18%)</td><td align="right" valign="middle" rowspan="1" colspan="1">1 (7.7%)</td><td align="right" valign="middle" rowspan="1" colspan="1">3 (13%)</td><td align="right" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0; 25&#x02013;44</td><td align="right" valign="middle" rowspan="1" colspan="1">21 (64%)</td><td align="right" valign="middle" rowspan="1" colspan="1">5 (38%)</td><td align="right" valign="middle" rowspan="1" colspan="1">11 (46%)</td><td align="right" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0; 45&#x02013;65</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 (18%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7 (54%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 (42%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Sex</bold>
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.200</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0; Female</td><td align="right" valign="middle" rowspan="1" colspan="1">19 (58%)</td><td align="right" valign="middle" rowspan="1" colspan="1">4 (31%)</td><td align="right" valign="middle" rowspan="1" colspan="1">10 (42%)</td><td align="right" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0; Male</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14 (42%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9 (69%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14 (58%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Race</bold>
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0; Asian</td><td align="right" valign="middle" rowspan="1" colspan="1">1 (3.0%)</td><td align="right" valign="middle" rowspan="1" colspan="1">0 (0%)</td><td align="right" valign="middle" rowspan="1" colspan="1">0 (0%)</td><td align="right" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0; Black</td><td align="right" valign="middle" rowspan="1" colspan="1">15 (45%)</td><td align="right" valign="middle" rowspan="1" colspan="1">10 (77%)</td><td align="right" valign="middle" rowspan="1" colspan="1">24 (100%)</td><td align="right" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0; White</td><td align="right" valign="middle" rowspan="1" colspan="1">7 (21%)</td><td align="right" valign="middle" rowspan="1" colspan="1">0 (0%)</td><td align="right" valign="middle" rowspan="1" colspan="1">0 (0%)</td><td align="right" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0; Not reported</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 (30%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (23%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Ethnicity</bold>
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.009</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0; Hispanic or Latino</td><td align="right" valign="middle" rowspan="1" colspan="1">19 (58%)</td><td align="right" valign="middle" rowspan="1" colspan="1">10 (77%)</td><td align="right" valign="middle" rowspan="1" colspan="1">19 (79%)</td><td align="right" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0; Non-Hispanic or non-Latino</td><td align="right" valign="middle" rowspan="1" colspan="1">4 (12%)</td><td align="right" valign="middle" rowspan="1" colspan="1">0 (0%)</td><td align="right" valign="middle" rowspan="1" colspan="1">5 (21%)</td><td align="right" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0; Not reported</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 (30%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (23%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Education level</bold>
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0; Less than high school</td><td align="right" valign="middle" rowspan="1" colspan="1">1 (3.0%)</td><td align="right" valign="middle" rowspan="1" colspan="1">5 (38%)</td><td align="right" valign="middle" rowspan="1" colspan="1">1 (4.2%)</td><td align="right" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0; High school graduate</td><td align="right" valign="middle" rowspan="1" colspan="1">4 (12%)</td><td align="right" valign="middle" rowspan="1" colspan="1">3 (23%)</td><td align="right" valign="middle" rowspan="1" colspan="1">7 (29%)</td><td align="right" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0; Higher education</td><td align="right" valign="middle" rowspan="1" colspan="1">9 (27%)</td><td align="right" valign="middle" rowspan="1" colspan="1">0 (0%)</td><td align="right" valign="middle" rowspan="1" colspan="1">15 (63%)</td><td align="right" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0; Graduate education</td><td align="right" valign="middle" rowspan="1" colspan="1">3 (9.1%)</td><td align="right" valign="middle" rowspan="1" colspan="1">0 (0%)</td><td align="right" valign="middle" rowspan="1" colspan="1">0 (0%)</td><td align="right" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0; Not reported</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16 (48%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 (38%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (4.2%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Underlying conditions</bold>
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0; None</td><td align="right" valign="middle" rowspan="1" colspan="1">27 (82%)</td><td align="right" valign="middle" rowspan="1" colspan="1">0 (0%)</td><td align="right" valign="middle" rowspan="1" colspan="1">1 (4.2%)</td><td align="right" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0; At least one</td><td align="right" valign="middle" rowspan="1" colspan="1">6 (18%)</td><td align="right" valign="middle" rowspan="1" colspan="1">2 (15%)</td><td align="right" valign="middle" rowspan="1" colspan="1">6 (25%)</td><td align="right" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0; Two or more</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11 (85%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17 (71%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>COVID-19 positive before first fingerstick</bold>
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.053</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0; Yes</td><td align="right" valign="middle" rowspan="1" colspan="1">10 (30%)</td><td align="right" valign="middle" rowspan="1" colspan="1">6 (46%)</td><td align="right" valign="middle" rowspan="1" colspan="1">15 (63%)</td><td align="right" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0; No</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23 (70%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7 (54%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9 (38%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr></tbody></table><table-wrap-foot><fn><p><sup>1</sup>&#x000a0;<italic toggle="yes">n</italic> (%); <sup>2</sup> Fisher&#x02019;s exact test; Pearson&#x02019;s Chi-squared test.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vaccines-12-01312-t002"><object-id pub-id-type="pii">vaccines-12-01312-t002_Table 2</object-id><label>Table 2</label><caption><p>A total of 271 capillary blood samples were collected from 70 subjects in three cohorts: control (<italic toggle="yes">n</italic> = 33), HD (<italic toggle="yes">n</italic> = 13), and TR (<italic toggle="yes">n</italic> = 24). Among them, 43 subjects were vaccinated with BNT162b2, including those who received homologous (<italic toggle="yes">n</italic> = 8) and heterologous boosters (<italic toggle="yes">n</italic> = 7), and 25 subjects were vaccinated with CoronaVac. Statistical comparisons for categorical variables were assessed using Pearson&#x02019;s Chi-squared test and Fisher&#x02019;s exact test.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-bottom:solid thin;border-top:solid thin" rowspan="1" colspan="1">Characteristic</th><th align="right" valign="middle" style="border-bottom:solid thin;border-top:solid thin" rowspan="1" colspan="1">Control, <italic toggle="yes">n</italic> = 33&#x000a0;<sup>1</sup></th><th align="right" valign="middle" style="border-bottom:solid thin;border-top:solid thin" rowspan="1" colspan="1">Hemodialysis, <italic toggle="yes">n</italic> = 13&#x000a0;<sup>1</sup></th><th align="right" valign="middle" style="border-bottom:solid thin;border-top:solid thin" rowspan="1" colspan="1">Transplant, <italic toggle="yes">n</italic> = 24&#x000a0;<sup>1</sup></th><th align="right" valign="middle" style="border-bottom:solid thin;border-top:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value&#x000a0;<sup>2</sup></th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Vaccine doses</bold>
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0; One dose</td><td align="right" valign="middle" rowspan="1" colspan="1">11 (33%)</td><td align="right" valign="middle" rowspan="1" colspan="1">5 (38%)</td><td align="right" valign="middle" rowspan="1" colspan="1">2 (8.3%)</td><td align="right" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0; Two doses</td><td align="right" valign="middle" rowspan="1" colspan="1">20 (61%)</td><td align="right" valign="middle" rowspan="1" colspan="1">4 (31%)</td><td align="right" valign="middle" rowspan="1" colspan="1">11 (46%)</td><td align="right" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0; Fully vaccinated and one booster</td><td align="right" valign="middle" rowspan="1" colspan="1">2 (6.1%)</td><td align="right" valign="middle" rowspan="1" colspan="1">2 (15%)</td><td align="right" valign="middle" rowspan="1" colspan="1">10 (42%)</td><td align="right" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0; Two or more boosters</td><td align="right" valign="middle" rowspan="1" colspan="1">0 (0%)</td><td align="right" valign="middle" rowspan="1" colspan="1">0 (0%)</td><td align="right" valign="middle" rowspan="1" colspan="1">1 (4.2%)</td><td align="right" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0; Not reported</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (15%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Vaccine type (prime schedule)</bold>
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.066</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0; BNT162b2</td><td align="right" valign="middle" rowspan="1" colspan="1">25 (76%)</td><td align="right" valign="middle" rowspan="1" colspan="1">7 (64%)</td><td align="right" valign="middle" rowspan="1" colspan="1">11 (46%)</td><td align="right" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0; CoronaVac</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8 (24%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 (36%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13 (54%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Booster schedule</bold>
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.700</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0; Heterologous</td><td align="right" valign="middle" rowspan="1" colspan="1">0 (0%)</td><td align="right" valign="middle" rowspan="1" colspan="1">1 (50%)</td><td align="right" valign="middle" rowspan="1" colspan="1">6 (55%)</td><td align="right" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0; Homologous</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (100%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (50%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 (45%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>COVID-19 positive before first fingerstick</bold>
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.053</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0; Yes</td><td align="right" valign="middle" rowspan="1" colspan="1">10 (30%)</td><td align="right" valign="middle" rowspan="1" colspan="1">6 (46%)</td><td align="right" valign="middle" rowspan="1" colspan="1">15 (63%)</td><td align="right" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0; No</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23 (70%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7 (54%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9 (38%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>COVID-19 positive during the study</bold>
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;0.900</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0; Yes</td><td align="right" valign="middle" rowspan="1" colspan="1">8 (24%)</td><td align="right" valign="middle" rowspan="1" colspan="1">2 (15%)</td><td align="right" valign="middle" rowspan="1" colspan="1">5 (21%)</td><td align="right" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0; Not reported</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25 (76%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11 (85%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19 (79%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr></tbody></table><table-wrap-foot><fn><p><sup>1</sup>&#x000a0;<italic toggle="yes">n</italic> (%); <sup>2</sup> Fisher&#x02019;s exact test; Pearson&#x02019;s Chi-squared test.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vaccines-12-01312-t003"><object-id pub-id-type="pii">vaccines-12-01312-t003_Table 3</object-id><label>Table 3</label><caption><p>A total of 11 independent variables were explored in association with the responses of the SARS-CoV-2 anti-Spike IgG antibody. Statistical significance was determined based on a 95% confidence interval (CI) for the standard coefficient (<inline-formula><mml:math id="mm9" overflow="scroll"><mml:mrow><mml:mi>&#x003b2;</mml:mi></mml:mrow></mml:math></inline-formula>).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-bottom:solid thin;border-top:solid thin" rowspan="1" colspan="1">Variable</th><th align="right" valign="middle" style="border-bottom:solid thin;border-top:solid thin" rowspan="1" colspan="1">
<inline-formula>
<mml:math id="mm10" overflow="scroll"><mml:mrow><mml:mstyle mathvariant="bold"><mml:mi mathvariant="bold-italic">&#x003b2;</mml:mi></mml:mstyle></mml:mrow></mml:math>
</inline-formula>
</th><th align="right" valign="middle" style="border-bottom:solid thin;border-top:solid thin" rowspan="1" colspan="1">95% CI&#x000a0;<sup>1</sup></th><th align="right" valign="middle" style="border-bottom:solid thin;border-top:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Time point</bold>
</td><td align="right" valign="middle" rowspan="1" colspan="1">
</td><td align="right" valign="middle" rowspan="1" colspan="1">
</td><td align="right" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">1</td><td align="right" valign="middle" rowspan="1" colspan="1">&#x02014;</td><td align="right" valign="middle" rowspan="1" colspan="1">&#x02014;</td><td align="right" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">2</td><td align="right" valign="middle" rowspan="1" colspan="1">0.42</td><td align="right" valign="middle" rowspan="1" colspan="1">&#x02212;0.04, 0.89</td><td align="right" valign="middle" rowspan="1" colspan="1">0.076</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">3</td><td align="right" valign="middle" rowspan="1" colspan="1">0.63</td><td align="right" valign="middle" rowspan="1" colspan="1">0.17, 1.10</td><td align="right" valign="middle" rowspan="1" colspan="1">0.008</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">4</td><td align="right" valign="middle" rowspan="1" colspan="1">0.54</td><td align="right" valign="middle" rowspan="1" colspan="1">0.10, 0.98</td><td align="right" valign="middle" rowspan="1" colspan="1">0.018</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.90</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.43, 1.4</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Cohort</bold>
</td><td align="right" valign="middle" rowspan="1" colspan="1">
</td><td align="right" valign="middle" rowspan="1" colspan="1">
</td><td align="right" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Control</td><td align="right" valign="middle" rowspan="1" colspan="1">&#x02014;</td><td align="right" valign="middle" rowspan="1" colspan="1">&#x02014;</td><td align="right" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Hemodialysis</td><td align="right" valign="middle" rowspan="1" colspan="1">1.30</td><td align="right" valign="middle" rowspan="1" colspan="1">&#x02212;0.13, 2.80</td><td align="right" valign="middle" rowspan="1" colspan="1">0.072</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Transplant</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.34</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.53, 1.20</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.400</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Vaccine doses</bold>
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.76</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.20, 1.30</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.008</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Age</bold>
</td><td align="right" valign="middle" rowspan="1" colspan="1">
</td><td align="right" valign="middle" rowspan="1" colspan="1">
</td><td align="right" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">18&#x02013;24</td><td align="right" valign="middle" rowspan="1" colspan="1">&#x02014;</td><td align="right" valign="middle" rowspan="1" colspan="1">&#x02014;</td><td align="right" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">25&#x02013;44</td><td align="right" valign="middle" rowspan="1" colspan="1">&#x02212;0.52</td><td align="right" valign="middle" rowspan="1" colspan="1">&#x02212;1.4, 0.35</td><td align="right" valign="middle" rowspan="1" colspan="1">0.200</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">45&#x02013;65</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.41</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.30, 1.1</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.300</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Sex</bold>
</td><td align="right" valign="middle" rowspan="1" colspan="1">
</td><td align="right" valign="middle" rowspan="1" colspan="1">
</td><td align="right" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Female</td><td align="right" valign="middle" rowspan="1" colspan="1">&#x02014;</td><td align="right" valign="middle" rowspan="1" colspan="1">&#x02014;</td><td align="right" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Male</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.39</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1.10, 0.31</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.300</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Underlying conditions</bold>
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.98</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1.60, &#x02212;0.40</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>COVID-19 positive before first fingerstick</bold>
</td><td align="right" valign="middle" rowspan="1" colspan="1">
</td><td align="right" valign="middle" rowspan="1" colspan="1">
</td><td align="right" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">No</td><td align="right" valign="middle" rowspan="1" colspan="1">&#x02014;</td><td align="right" valign="middle" rowspan="1" colspan="1">&#x02014;</td><td align="right" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.10</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.23, 1.90</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.014</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Vaccine type (prime schedule)</bold>
</td><td align="right" valign="middle" rowspan="1" colspan="1">
</td><td align="right" valign="middle" rowspan="1" colspan="1">
</td><td align="right" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BNT162b2</td><td align="right" valign="middle" rowspan="1" colspan="1">&#x02014;</td><td align="right" valign="middle" rowspan="1" colspan="1">&#x02014;</td><td align="right" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CoronaVac</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.80</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.81, 2.80</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Booster schedule</bold>
</td><td align="right" valign="middle" rowspan="1" colspan="1">
</td><td align="right" valign="middle" rowspan="1" colspan="1">
</td><td align="right" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Heterologous</td><td align="right" valign="middle" rowspan="1" colspan="1">&#x02014;</td><td align="right" valign="middle" rowspan="1" colspan="1">&#x02014;</td><td align="right" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Homologous</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.40</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.30, 2.50</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.014</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Education level</bold>
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.01</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.68, 0.66</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;0.900</td></tr></tbody></table><table-wrap-foot><fn><p><sup>1</sup> CI = Confidence Interval.</p></fn></table-wrap-foot></table-wrap></floats-group></article>